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I)  Introduction and scientific issue 
1. VEGF characteristics and receptors 
VEGF (Vascular Endothelial Growth Factor) is an important signal molecule for 
vasculogenesis and angiogenesis [1, 2] having influence on the formation of 
blood vessels in the embryo [3, 4] as well as having an impact on the vascular 
system in the adult body.  VEGF describes a family of proteins with different 
functions. Seven different isoforms of VEGF are known: VEGF A-F and PlGF 
(Placental Growth Factor) [5]. Originally, it was described as Vascular 
Permeability Factor (VPF) which was discovered in the surrounding of tumor 
cells leading to vascular leakage [6]. In 1989, two groups independently purified 
a mitogen that is characteristic for endothelial cells, which they called VEGF 
and vasculotropin, respectively [7, 8]. 
 
VEGFs are predominantly produced by endothelial, hematopoietic, and stromal 
cells in response to hypoxia and upon stimulation by growth factors such as 
transforming growth factor b (TGFb), interleukins, or platelet-derived growth 
factors (PDGFs) [9]. 
1.1. VEGF functions 
The proliferative action of VEGF is predominantly restricted to vascular 
endothelial cells as they almost exclusively express VEGF receptors [10]. 
Besides, mitogenetic effects of VEGF in lymphocytes, retinal pigment epithelial 
cells and Schwann cells have been described (reviewed by [10]). In conclusion, 
binding of VEGF to non-endothelial cells seems to have effects different from 
proliferation- such as the induction of monocyte migration [11]. 
The vital role of VEGF in vasculogenesis was demonstrated with the help of two 
knockout mice studies in 1996 [3, 4]: the loss of a single VEGF allele had a 
disastrous impact on the de novo formation of blood vessels. In the studies, this 
led to embryonic death between days 11 and 12.  
Apart from the above described functions of proliferation and migration and its 
role in vasculogenesis, VEGF has a couple of other functions contributing to its 
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outstanding role as the angiogenetic factor: the induction of plasminogen 
activators [12] and interstitial collagenase expression [13] in endothelial cells, 
the stimulation of microvascular leakage and thus increasing the permeability of 
capillary vessels to macromolecules [6] (which led to its originally used name 
VPF) and hexose transport [14]. Besides, VEGF acts as a survival factor for 
newly formed retinal vessels [15]. These additional functions contribute to 
angiogenesis by delivering energy, facilitating migration and maintaining the 
process.   
There are several splice variants of VEGF with specific functions in blood and 
lymph vessel formation and homeostasis [10]. 
1.2. VEGF gene and protein structure, VEGF isoforms  
Vincenti et al. assigned the Vascular Endothelial Growth Factor Gene to Human 
Chromosome 6p21.3 in 1996 [16]. The VEGF coding region spans ~14 kb and it 
contains eight exons [17, 18]. Six different proteins are produced by alternative 
splicing of the primary transcript (pre-mRNA) generated from a single-copy 
gene.  
VEGF is secreted as a (covalently linked homo-) dimer [10]. Through the work 
of several groups, six isoforms of VEGF have been found and they differ in 
length ranging from 121 to 206 amino acid residues (VEGF 121-206) [18-22]. 
Thus,  the known splice variants to date of human VEGF are: VEGF 121, VEGF 
145, VEGF 165, VEGF 183, VEGF 189  and VEGF 206. They differ by the presence or 
absence of sequences encoded by exons 6 and 7 [18]. The isoforms are 
secreted by several cell types and in different frequencies. Most cells appear 
preferentially to express VEGF121, VEGF165 and VEGF189 [10] with VEGF165  as 
the most biologically active variant. The other splice variants seem to be found 
less frequently.  
Further differences between the isoforms can be found in their heparin binding 
affinity and in how much they are more or less cell and ECM associated or 
freely released from producing cells. All forms, except homodimeric VEGF121, 
which is weakly acid, can bind heparin in vitro and bind heparin derivatives of 
the extracellular matrix in vivo [16]. This is due to the presence or absence of 
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sequences of amino acids encoded by exon 6 that determine the acid or basic 
character of the proteins [7, 8, 23]. For example, VEGF165 has moderate affinity 
for heparin and 50-70% remain cell and ECM associated [20]. VEGF121 is freely 
released whereas VEGF189 and VEGF206 stay completely sequestered in the 
ECM and partly at the cell surface and bind heparin strongly [20].    
1.3. VEGF expression 
VEGF mRNA is expressed in a variety of normal adult tissues (predominantly 
endothelial, hematopoietic, and stromal cells) and during embryogenesis but 
also in many tumors (see below). VEGF mRNA expression is strongly and 
rapidly up regulated by oxygen deprivation in vitro in several cell types as well 
as by ischemia in vivo [16, 24-26]. This was particularly observed in necrotic 
areas of tumors [27]. The secretion of VEGF is triggered by hypoxia in cells 
[27]. When there is a shortage of oxygen, cells produce hypoxia-induced 
factors, which lead to the distribution of VEGF and finally to angiogenesis in 
order to compensate for the oxygen deficit.  
Moreover, many cytokines and growth factors up regulate VEGF mRNA or 
induce VEGF release (among these are different tumor growth and tumor 
necrosis factors TNF-ALPHA, TGF-ALPHA, epidermal growth factor EGF, 
interleukins etc.) [10].  
1.4. VEGF secretion, VEGF-related proteins 
Besides PlGF, there are a couple of VEGF-related growth factors, namely 
VEGF -B, -C, -D and –E and platelet- derived growth factor (PDGF). Thus, the 
„originally“ discovered VEGF and the one considered to be the major regulator 
of angiogenesis and vascular permeability [28] is often also referred as VEGF -
A. In humans, the VEGF-related proteins are also ligands for the different VEGF 
receptors. VEGF- C and –D are mainly involved in lymphangiogenesis and 
VEGF-E was found to be a viral variant of VEGF 165 [10]. PlGF is believed to 
play important roles in various physiological and pathological processes and 
VEGF-B resembles PlGF in many aspects. VEGF-B has a wide tissue 
distribution but it is particularly abundant in the heart and skeletal muscle 
(reviewed by [10]). 
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1.5. VEGF Receptors 
Structurally and functionally the receptors are membrane-bound [29] type V 
tyrosine kinases, whose extracellular domains consist of seven 
immunoglobulin-like (Ig-like) domains followed by a membrane-spanning region 
and a conserved intracellular tyrosine kinase domain interrupted by a kinase 
insert sequence [9, 10, 30]. Three different receptors have been identified 
(VEGF receptor-1, -2, and -3) [9]. In addition, heparan sulphate proteoglycans 
and neutropilins also interact with ligands. The neutropilins are isoform-specific 
receptors for certain VEGF family members [10]. Among others, those 
previously named partly act as co-receptors and are of importance for VEGF165. 
Neuropilin-1, for example, is likely to enhance the binding of VEGF165 to 
VEGFR-2 [31]. 
 
The first receptor discovered was flt-1, also known as VEGFR-1, a ~180-kDa 
glycoprotein that has the highest affinity for VEGF [30, 32]. Its functions are 
described as endothelial maintenance and vasculogenesis and it also has 
different roles in other cell types (reviewed by [10]). Subsequently, KDR 
(kinase-insert-domain-containing receptor, also known as flk-1 or VEGFR-2 [33] 
and flt-4  or VEGFR-3 was discovered.  VEGFR-2 is a 200-230 kDa high-affinity 
receptor for VEGF [33], whereas VEGFR-3 (flt-4) does not bind VEGF. 
Expression of VEGFR-3 is restricted mainly to the lymphatic endothelium of 
adult tissues [34-36] and is possibly involved in the control of lymphagiogenesis 
[10]. There seems to be evidence that most endothelial cell responses to VEGF 
are mediated by VEGFR-2 [10]. 
These receptors have different affinities for VEGF and VEGF-related proteins 
as well as for different isoforms: VEGF only binds to receptor types 1 and 2, 
PlGF and VEGF-B only bind to receptor type 1 and VEGF-C and VEGF-D only 
bind to receptors type 2 and 3. VEGF-E and VEGF-F bind to receptor type 2 
(reviewed by [10]). 
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2. VEGF and the kidney 
2.1. Anatomy and function of the glomerulus 
The following text contains information combined from the following sources: 
[37-39]  
The kidney plays an important role in the regulation of blood pressure, acid-
base balance and in the production of hormones. However, its main function is 
the ultrafiltration of plasma and the production of urine with the glomerulus as 
the main site of action. The human kidney consists of lobi renales with an inner 
medulla and an outer cortex. Besides other important renal components, the 
glomeruli are located in the cortex.  
Glomerulus (and Bowman´s capsule), proximal, intermediate and the distal 
tubules and collecting duct form so-called nephrons (the functional unit) in 
which urine is produced. 
Kidney glomeruli and ultrafiltration 
Each glomerulus contains one arterial capillary arranged in loops, beginning as 
the vas afferens and ending as the vas efferens. The urinary and the blood 
space of the glomerulus are separated by the glomerular capillary wall (figure 
1). The glomerular capillary wall is also considered as the visceral portion of 
Bowman´s capsule (see below) and it consists of three distinct but closely 
interacting layers: the fenestrated endothelium with its glycocalyx, the 
podocytes with their interdigitated foot processes and slit diaphragms, and the 
intervening glomerular basement membrane (GBM) [40] (figure 2).  
In between the capillaries lies the mesangium with the mesangium cells. They 
stabilize the capillary tuft, contribute to the high glomerular filtration pressure by 
contraction and act as phagocytes. 
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Figure 1: Schematic presentation of the glomerular capillary and (in detail) 
glomerular capillary wall 
In the glomerular capillary, urinary space (UR, outside) and blood space (BL, inside) are 
separated by the capillary wall. The glomerular capillary wall (detail image) consists of three 
distinct but closely interacting layers: the fenestrated endothelium with its glycocalyx (glycocalyx 
not shown), the podocytes with their interdigitated foot processes and slit diaphragms, and the 
intervening glomerular basement membrane (GBM). 
Figure taken from [41] by courtesy of the authors, modified. 
 
 
Figure 2: A representative example of fenestrated glomerular endothelium 
“Blood lumen on the upper part, urinary space on the lower part of the image… 
GBM= glomerular endothelial basement membrane, CL= capillary lumen, POD= podocyte. 
Arrows mark fenestrae, asterisks mark podocyte foot processes, arrowheads mark podocyte slit 
diaphragma.” [42] 
Transmission electron microscopy (magnification x 20.000), own picture, sample: Aflibercept 
day1, published in [42]. 
BL 
UR 
UR 
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The glomerulus works as a protein sieve, the glomerular capillary wall is thus 
also called the glomerular filtration barrier which requires the contribution of 
all three layers of the glomerular capillary wall: endothelium, GBM, and 
podocytes [40, 43] as well as the glycocalyx [44]. Filtration is driven by Starling 
forces acting across the glomerular capillary wall, and depends on its large 
surface area and extremely high water permeability [44]. 
Glomerular endothelial cells are extremely flat and perforated by trans-cellular 
pores- the fenestrae. The existence of fenestrae is VEGF-dependent and is 
responsible for the glomerular endothelium´s high water permeability [44]. 
Podocytes are highly differentiated epithelial cells on the visceral side of the 
glomerular capillary tuft [45]. Their long primary and secondary foot processes 
enwrap the glomerular capillaries and interdigitate, leaving filtration slits with a 
constant width of 30 – 40 nm in between [45]. The existence of a slit diaphragm, 
a highly structured layer of interacting transmembrane proteins [45] – including 
nephrin- which covers the space between podoycte processes and fenestrae of 
endothelial cells is still an issue of discussion as it was not observed in all 
studies. It was not seen for example by Satchell et al. [46] but this view is 
challenged by others [47-49]. It is supposed to be crucial in establishing the size 
and charge selectivity of the filtration barrier and is an important platform for 
intracellular signaling pathways [45, 50]. 
Bowman´s capsule 
This structure is a delicate capsule consisting of a parietal and visceral layer of 
epithelium.  A simple squamous epithelium forms the parietal layer, which is 
separated from the visceral layer by the so-called Bowman´s space (urinary 
space) into which the filtrate enters. This epithelium is turned into the epithelium 
of the tubules. Podocytes on a thickened glomerular basement membrane form 
the visceral layer lying on the glomerular capillaries [39, 51]. 
As any epithelium, the parietal layer also contains a basement membrane. In 
this case it is prominent, thick and consists of three layers: the thin lamina 
lucida, the thicker lamina densa and the outer lamina reticularis (lamina 
fibroreticularis) containing an interweaving network of reticular fibers [51]. 
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Proximal and distal tubules and collecting ducts 
All the different sections of the tubules have a single-layered epithelium but 
differ in a couple of morphologic and functional features and their localization 
within the kidney [51]. In the course of passing the functional system of the 
nephron, the primary urine filtered in the glomeruli is modified in the system of 
tubules and collecting ducts and leaves the kidney through the renal pelvis into 
the ureter [39]. 
At the urinary pole of the glomerulus the tubule system starts with the proximal 
tubules (initially pars recta, followed by pars convolute). Its single-layered 
cuboidal epithelium with its characteristic brush border and round cell nuclei 
forms the continuation of the parietal layer of Bowman´s capsule. Its densely 
packed microvilli  and vesicles in the apical cell part and mitochondria in the 
infoldings of the basal plasma membrane [51] are expression of the high 
absorption and secretion in this part of the kidney.  
The following smaller calibered intermediate tubules have a large lumen and 
flattened single-layered epithelium. The nuclei are lenticular and the nucleus-
carrying cell part projects into the lumen. These cells do not carry microvilli or 
have basal infoldings [51]. 
The distal tubules (pars convolute and pars recta) have a couple of similarities 
with the proximal tubules: round cell nuclei and basal infoldings and a single-
layered cuboidal epithelium. In contrast to the proximal tubules the epithelium is 
flatter and does not contain a brush border. Moreover, it has a smaller diameter 
and a slightly larger lumen [51]. 
The connecting tubules lead to the collecting duct system. Both cell types show 
a single-layered cuboidal epithelium with distinct cell borders. Two different cell 
types can be distinguished: intercalated cells (with a high amount of organelles 
and short microvilli) and principal cells. As the ducts get larger and are 
converted to Ductus papillares, the cells become higher prismatic and the 
amount of principal cells increase [51]. 
Localization of the different structures in the kidney parenchyma 
The kidney parenchyma is organized in pyramidal lobi renales which again 
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consist of cortex and medulla (table 1). The tubules system runs from the cortex 
to the medulla, makes a hairpin turn back to the cortex and is there continued to 
the collecting duct system. The descending pars recta of proximal tubules and 
pars descendens of intermediate tubules and the pars ascendens of 
intermediate tubules and pars recta of distal tubules are also called the loop of 
Henle [39](adapted from [51]). 
 
Table 1: Histological organization of the kidney parenchyma 
Adapted from [51] 
 
Cortex  
- Labyrinth 
- Glomeruli 
- pars convoluta of proximal and distal tubules 
Cortex 
- cortical columns at the 
contact area of two lobi 
- pars recta of proximal and distal tubules 
- collecting ducts 
Medulla 
- outer segment with stripes 
- same structures as cortical columns 
Medulla 
- inner segment 
- intermediate tubules 
- pars recta of distale tubules 
- collecting ducts 
- ductus papillares 
 
Due to the nature of my study, I was mainly interested in the glomeruli. Thus, I 
selected parts of the kidney cortex and besides glomeruli, mainly proximal and 
distal tubules can be seen on my pictures (Table 2). 
 
Table 2: Recognition of important histological kidney structures 
Adapted from [51] and own observations  
 
Glomerular endothelial cells Extremely flat and perforated by  
fenestrae, prominent nuclei, form the 
inner surface of glomerular capillaries. 
Podocytes Epithelial cells with cell body and large 
and small branched foot processes in 
association with the glomerular 
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basement membrane of capillaries, 
numerous coated vesicles and coated 
pits along the basolateral domain, 
prominent endoplasmic reticulum and 
Golgi apparatus. 
Glomerular mesangial cells  Prominent nuclei, irregular shape, 
many cell processes with 
microfilaments, surrounded by 
amorphous mesangial matrix. 
Cells of parietal part of Bowman´s 
capsule 
Exhibit a cilium and show numerous 
vesicles and intermediate filaments 
[51], with a thick basement membrane 
and prominent lamina reticularis. 
Proximal tubules Single-layered cuboidal epithelium with 
thick brush border, many mitochondria, 
indistinct lateral borders and basal 
infoldings. 
Intermediate tubules Single-layered flattened epithelium, 
large lumen, nuclei projecting into 
lumen. 
Distal tubules Single-layered flatter cuboidal 
epithelium, no/less brush border, 
smaller diameter, larger lumen, cells 
paler, bulge into the lumen, indistinct 
lateral borders. 
Collecting duct system Single-layered cuboidal to higher 
prismatic epithelium with distinct cell 
borders, intercalated cells and 
principal cells. 
 
3.2. VEGF under physiological conditions 
The two key vascular growth factor families implicated in glomerular biology and 
function are the vascular endothelial growth factors (VEGFs) and the 
angiopoietins [52]. VEGF was found in the kidney during embryogenesis [53] 
and in the adult kidney [54]. Further indications were found that the interaction 
between VEGF and its receptors is vital for the development of the kidney as 
well as for the maintenance of the filtration barrier [55]. VEGF production is 
induced by hypoxia [56] (see below), but as the kidney is not always hypoxic 
and as VEGF is constantly produced in the healthy state, other processes have 
to be involved. Integrins were suggested as non-hypoxic mediators of 
constitutive VEGF podocyte expression [41, 56]. Also, it has been found that 
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VEGF is up-regulated by renin and angiotensin II [57, 58]. In turn, VEGF has a 
stimulating influence on the production of angiotensin II and expression of 
angiotensin-converting enzyme [59, 60]. These findings seem to indicate a 
correlation between VEGF and blood pressure. 
There is agreement that in the kidney, podocytes are (except for the distal 
tubule and collecting duct) the main site of local VEGF production [41, 61, 62]. 
Besides, different groups have found VEGF production in the glomerulus in vitro 
in glomerular epithelial cells [62], endothelial cells [63] and mesangial cells [64]. 
VEGF receptor (VEGFR) tyrosine kinases are expressed by both podocytes 
and glomerular endothelial cells [45].  
The glomerular epithelium is fenestrated. This is supposed to enable the kidney 
to perform its high rate of glomerular ultrafiltration. It has been suggested that 
VEGF produced by glomerular epithelial cells may be vital for the maintenance 
of the fenestrated phenotype of glomerular epithelial cells [62, 65, 66]- 
especially with VEGFR-2 [45]. Simon et al. were able to localize VEGF mRNA 
in glomerular epithelia and collecting duct cells and the medulla [65]. These and 
findings by other groups led to the speculation that the constitutive expression 
of VEGF in the adult kidney may be required for the function of VEGF receptor 
positive- fenestrated endothelia in glomeruli and post-glomerular vessels [65]. 
 
In conclusion, VEGF is mainly produced by podocytes and mainly affects 
glomerular epithelial cells. For the development of the kidney and the integrity 
and function of the glomerular filtration barrier, VEGF is essential [41, 67].  Its 
surplus or reduction may have a pathological impact.  
2.3. VEGF under pathological conditions 
VEGF can also play a role in the pathogenesis of renal diseases. VEGF 
podocyte production must be tightly regulated as not only a lack, but also a 
surplus of VEGF may damage the glomerular filtration barrier [41]. In preclinical 
murine models, heterozygous deletion of VEGF in podocytes led to a loss of 
endothelial cell fenestration, a loss of podocytes, mesangiolysis, and 
proteinuria, suggesting that VEGF has a critical protective role in the 
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pathogenesis of microangiopathic process [68], reviewed by [61]. 
As mentioned above, lack of oxygen is the main inducer of VEGF. The 
induction of VEGF by hypoxia was demonstrated in mice in vivo [54]. The effect 
was highest in brain, but also occurred in the kidney (tubular cells), testis, lung, 
heart, and liver. Interestingly, these authors found that the organ-specific 
distribution of VEGF and its receptors changes under the influence of hypoxia. 
 
VEGF over-expression was found to induce proteinuria, renal failure and 
neonatal death [69]. As it is a highly potent inductor of microvascular 
permeability, dysfunctions in the VEGF system might lead to leakage in the 
glomerular filtration barrier. Its upregulation during mesangioproliferative 
disease was described [70]. Additionally, VEGFR receptors were also found on 
human mesangial cells in vitro and mesangial cell proliferation ex vivo was 
induced by VEGF165 [71]. In the same study, expression of VEGF receptors was 
found on the mesangium in mesangioproliferative disease. These facts might 
be of interest in understanding the pathogenesis of renal diseases, as 
mesangial cell proliferation is a common response of the glomerulus to diverse 
injuries [71]. Further increased VEGF expression was found in chronic renal 
allograft rejection [72], indicating that VEGF plays a role in the pathogenesis of 
rejection and in renal cysts of patients with adult polycystic kidney disease [73]. 
Also of importance, excessive VEGF-A expression in podocytes was reported in 
diabetic nephropathy [74]. Moreover, it was reported that VEGF serum levels 
are increased in renal cell carcinoma [75] and that VEGF levels corresponded 
with the size and grade of the tumor [76], indicating that VEGF levels may 
correlate with patients´ outcome [66]. 
 
Of interest, also a decrease of VEGF can indicate a pathological situation. One 
study showed a decreased VEGF expression in patients with various renal 
diseases [77]. VEGF expression was decreased or absent in sclerotic glomeruli, 
amyloidosis and glomerulonephritis. 
On the other hand, there are studies showing VEGF´s beneficial effects in 
glomerular diseases. VEGF is supposed to support the healing by stimulation of 
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capillary repair. For example in glomerulonephritis, glomerular endothelial cells 
have an active role in the glomerular response to injury by VEGF-mediated 
endothelial proliferation [78]. A study of Kim et al. in rats shows that VEGF 
serves to limit thrombotic microangiopathy which is characterized by renal 
microvascular injury [79] and Ostendorf et al. documented that VEGF may play 
a distinct role in small vessel repair after a given injury to the kidney [80]. 
 
In summary, strict regulation of VEGF seems to be extremely sensitive to the 
development and function of the kidney and especially a vital factor of the 
healthy glomerular filtration barrier.  
3. VEGF and the eye 
3.1. Anatomy and function of the retina (reviewed by [81] and [82]) 
The retina is approximately 0.5 mm thick and lines the back of the eye. The 
macula or macula lutea is a small region of the retina with a diameter of about 
5,5 mm where the cone photoreceptors, responsible for acute and color vision, 
are predominant. Its center is named fovea centralis. Posterior to the 
photoreceptors lies the retinal pigment epithelium [83]. 
 
About 15° nasaly lies the optic nerve and from its center radiate the major blood 
vessels of the retina. The optic nerve contains the ganglion cell axons running 
to the brain and, additionally, incoming blood vessels that open into the retina to 
vascularize the retinal layers and neurons [82]. In contrast to the rest of the 
retina, the macula/ fovea is physiologically avascular.  
 
The functional anatomic complex of the macula region contains photoreceptors, 
the retinal pigment epithelium cells (RPE), the Bruch´s membrane and the 
choroid (figure 3). The retina has an inverse structure so that light must pass 
the whole way through the retina before activating the rods and cones.  The 
ganglion cells lie innermost in the retina closest to the lens and front of the eye, 
and the photosensors lie outermost in the retina against the pigment epithelium 
and choroid [82]. 
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The two types of photoreceptors, namely rods and cones, absorb photons of 
light. They consist of inner and outer segments and form monolayers. Their 
outer segments are in tight contact with retinal pigment epithelium cells 
containing visual pigments and being vital for the function und survival of 
photoreceptors, contributing to the blood-retina barrier and evacuating of 
metabolites (especially capturing, phagocytosis and contributing to the 
rebuilding of outer segments of photoreceptors) and delivering of nutrients [81]. 
Five layers of collagen and elastin form the Bruch´s membrane. It has the 
important task to separate the retina from the choroidal microvessels, thus 
separating neural from vascular structures. As both the RPE cells and the 
photoreceptors are physiologically avascular, the choroid/ choroidal system is 
responsible of the nutrition (with oxygen and microelements) of the formerly 
named via its choriocapillaris. Apart from the choriocapillaris, the central retinal 
artery is the second source of blood supply for the retina. 
3.2. VEGF and the retina 
Four AMD research, the interaction of VEGF with retinal pigment epithelial cells 
is of special interest. The data demonstrate that human retinal pigment 
epithelial cells can synthesize the secreted vascular endothelial growth factor in 
vitro and in situ [84]. The production and secretion of this factor by human 
retinal pigment epithelial cells may be important in the pathogenesis of ocular 
neovascularization as it acts as survival factor for newly formed retinal vessels 
[15]. Retinal pigment epithelial cells do not only produce VEGF, they are also 
target to the protein. VEGF was shown to induce proliferation [84, 85] and 
migration in these cells and they were shown to express both VEGFR-1 and 
VEGFR-2 [85].  
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Figure 3: Healthy retina-RPE-choroid complex in light microscopy (semi-thin 
section stained with toluidine blue) 
 “NFL nerve fiber layer; GCL ganglion cell layer; IPL inner plexiform layer; OPL outer plexiform 
layer; ONL outer nuclear layer; PR IS photo- receptor inner segments; PR OS photoreceptor 
outer segments; RPE retinal pigment epithelium; ChC Choriocapillaris; Ch Choroid; V choroidal 
vessel; M melanocyte. “[86] NFL not shown. 
Picture and description taken from [86] by courtesy of the authors. 
 
3.3. Anatomy and function of the iris and the ciliary body 
The iris 
The iris is –besides choroid and ciliary body- part of the middle layer of the eye 
which is also called uvea. It contains blood vessels, pigment cells and muscles 
and the number and disposition of pigment cells (melanocytes) determines the 
color of the eye. 
The pupil is the central aperture of the iris. The anterior surface of the iris is an 
incomplete layer of fibroblasts without a lining epithelium [87]. The stroma 
contains blood vessels and nerves and the sphincter and dilator pupillae 
muscles that are responsible to regulate the aperture of the pupil depending on 
lighting conditions. Only a double layer of pigmented epithelial cells that are 
reflected at the pupillary margin covers the posterior side [87] . The basal 
lamina of the inner layer (PPE= posterior pigment epithelium) faces the 
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lens.  The basal lamina of the outer layer (anterior pigment epithelium) is 
adjacent to the stroma of the iris [87] . The posterior pigment epithelium of the 
iris is continuous with the non-pigmented ciliary epithelium (figure 4). 
The ciliary body 
At the base of the iris the ciliary body extends from the limbus (corneoscleral 
junction) and the root of the iris to the ora serrata (the anterior limit of the retina 
and the choroid). The ciliary body is grossly subdivided into two portions, the 
pars plicata near the lens, also called the ciliary pocesses) and the pars plana 
[88] . Zonule fibers originate from the surface of the ciliary body between the 
ciliary processes to the lens. 
The ciliary body consists of smooth muscle fibers (ciliary muscles) and ciliary 
processes [89]. There are large diameter fenestrated (in the stroma of the ciliary 
processes) and smaller caliber non-fenestrated capillaries (which serve the 
ciliary muscle) in the center of these processes, which are covered by a double-
layered epithelium [88, 89]. 
This double- layered epithelium lines the complete inner surface of the ciliary 
body. One layer that is pigmented (containing melanin pigment, facing the 
ciliary stroma) and one layer is non-pigmented (facing the lens). This non-
pigmented layer is the continuation of the posterior pigment epithelium of the 
iris and the neurosensory retina at the ora serrata posteriorly continues it. The 
pigmented ciliary epithelium continues anteriorly as the anterior myoepithelium 
of the iris (which includes the iris sphincter muscle) and posteriorly as the 
pigmented epithelium of the retina. As a result of their embryogenic 
development, basement membrane of the non-pigmented ciliary epithelium 
faces the posterior chamber and that of the pigmented ciliary epithelium joins 
both epithelial layers to the ciliary body stroma with the apical surfaces of both 
layers facing one another [88].  
 
The ciliary body is responsible for the attachment of the lens and its functions 
are lens accommodation and aqueous humor production and secretion [89]. 
Moreover, it assists in aqueous humor drainage [88]. 
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Aqueous humor is vital for the nutrition of the avascular tissues of the eye. 
Moreover, it determines intraocular pressure. A selective barrier (called the 
blood-aqueous barrier) must be positioned between the bloodstream and the 
aqueous humor as a high amount of proteins would reduce optical efficiency 
and as antigents are not supposed to reach the anterior and posterior chambers 
of the eye [88]. Here, the fenestrated capillaries serve as a selective 
permeability barrier and also provide a reservoir from which aqueous humor is 
secreted by the ciliary epithelium through a complex system of intercellular and 
transcelular junctions [88, 89].  
After being secreted into the posterior chamber, the aqueous humor passively 
flows past the lens, through the pupil into the anterior chamber where it is 
drained through the trabecular meshwork in the iridocorneal angle into the canal 
of Schlemm (a circumferentially oriented vessel) and then into the venous 
system [88]. By extension of certain smooth muscle fibers and their tendons 
into the adjacent trabecular meshwork, the ciliary body can assist in the 
drainage of aqueous humor from the eye [88]. Any disturbance of this in- and 
outflow has direct impact on intraocular pressure. 
 
Ageing changes that can be expected in the ciliary body and the iris are 
increased pigmentation of the trabecular meshwork, an increase in the 
resistance to the outflow of aqueous humor with an increased risk of glaucoma 
[90] and thickening of the basement membrane of the pigmented ciliary 
epithelium [88]. The iris tends to become less reactive with age and loses 
pigment and also the shape and tone of ciliary body changes with age [90].  
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Figure 4: Overview of the transitions zone between iris (right side) and ciliary 
body, pars plicata (left side) 
Posterior side facing the lens on the upper part, anterior side facing the inside of the eye on the 
lower side of the picture. 
Iris: Asterisk marks the endothelium-free anterior surface of the iris. The posterior side facing 
the lens is covered by a double- layered epithelium. PPE= posterior pigment epithelium. The 
outer layer (APE= anterior pigment epithelium) is adjacent to the stroma of the iris. 
Arrowhead marks the transitions zone at the iris root where the posterior pigment epithelium of 
the iris passes into the non-pigmented ciliary epithelium (NCE) 
Ciliary body:  The inner surface of the ciliary processes is covered by a double-layered 
epithelium. One layer is pigmented (PCE= pigmented ciliary epithelium, containing melanin 
pigment, facing the ciliary stroma) and one layer is non-pigmented  (NCE= non pigmented 
ciliary epithelium, facing the lens). 
Semi-thin section, light microscopy, magnification x5000, sample: monkey, Aflibercept day1, 
picture from our group taken by Maximilian Ludinsky. 
 
3.4. VEGF and the ciliary body 
Only few studies on the role of VEGF-A in the ciliary body have been 
performed. Ford et al. revealed the role of VEGF-A in the embryogenesis of the 
ciliary body as well as in the homeostasis and in the maintenance of the 
fenestrated phenotype of its capillaries in the adult [89]. It seems that VEGF-A 
is expressed by the pigmented epithelium, whereas VEGFR2 is localized 
primarily to the capillary endothelium and non-pigmented epithelium [89]. 
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3.5. Age-related macular degeneration 
Age-related macular degeneration (AMD) is the most common cause of severe 
loss of vision and blindness in people over 50 years in the industrialized world 
(followed by glaucoma and diabetic retinopathy) [83]. It affects several dozen 
million of people worldwide [81]. 
Clinical classification 
In 2013, a clinical AMD classification was compiled by a committee of 30 
experts [91]. AMD was defined as: “fundus lesions assessed within 2 disc 
diameters of the fovea in persons older than 55 years“. This definition is 
supposed to separate AMD disease from pigmentary abnormalities or small 
drusen (<63 µm), also termed drupelets as they are part of physical aging 
process. Additionally, an early form of AMD was defined for persons having 
medium drusen (≥ 63-<125 µm), but without pigmentary abnormalities and 
persons with large drusen or with pigmentary abnormalities associated with at 
least medium drusen to have intermediate AMD [91].  
The most common form is the slowly progressive atrophic or dry AMD with 
around 85% of all AMD cases followed by advanced or late stage AMD, also 
called geographic atrophy AMD with 35 % of cases. The third and with 10-
15% of cases rarest but also rapidly progressing form is the exudative or wet 
AMD [91, 92], reviewed by [81]. 
Pathological features 
AMD is a disease of the outer retina. It results in atrophy of photoreceptors and 
retinal pigment epithelium accompanied with or without choroidal 
neovascularization (wet or dry AMD) [93].  As the macula is responsible of 
sharp vision, its damage threatens the ability to see fine details and colors. 
Additionally to vision incomfort or loss which drafts the patient to visit an 
ophthalmologist, further pathological features can be detected in AMD: the 
presence of drusen in the macula region (amorphous deposits accumulating 
extracellularly under the retina in the area between RPE and the inner 
collagenous zone of Bruchs membrane [92]), pigmentary abnormalities (hypo- 
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and/ or hyperpigmentation) of the retinal pigment epithelium (RPE) or newly 
formed subfoveal blood vessels originating from the choroid [81]. These go in 
line with RPE/photoreceptor degeneration and Bruch´s membrane disruption. 
RPE cells are the first to be affected. They undergo degeneration due to 
metabolic inefficacy, followed by the photoreceptors which are dependent on 
RPE cells [94]. 
As already mentioned, AMD and any other disease of the eye has to be 
distinguished from physiological aging processes. In the retina they include 
steady loss of photoreceptors, thickening of Bruch´s membrane, thinning of the 
choroid and forming of hard drusen in the periphery [93]. Many of these 
features can be found even stronger in AMD as well as additional soft macular 
drusen and other disease-specific changes [93]. The retina persists in a state of 
chronic inflammation and increased expression of certain cytokines and 
inflammasomes are a sign of its constant unsuccessful struggle to maintain 
ocular homeostasis which probably leads to tissue degeneration [93].  
Dry AMD 
Dry or geographic AMD is characterized by discrete regional loss of the retinal 
pigment epithelium accompanied by death of the overlying photoreceptors [95]. 
Till now, there is no approved therapy for dry AMD. 
Wet AMD 
The wet form of the disease is characterized by an abnormal growth of new 
blood vessel originating from the choroid through Bruch´s membrane toward the 
retina [95]. The newly formed blood vessels are abnormal because they are 
immaturely formed and leaky [95]. This process starting subretinal is called 
choroidal neovascularization of the retina and leads to pathologic fluid leakage 
and hemorrhage under and into the photoreceptor cell layer in the macula 
region [81] (figure 5). 
The pathogenesis of this formation of new blood vessels is still not clear. It 
includes local hypoxia due to the existence of drusen between RPE monolayer 
and Bruch´s membrane. The growing number and size of drusen, as well as the 
appearance of soft drusen, may lead to local detachment of RPE from Bruch´s 
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membrane and the choriocapillaries [81]. Others see the cause in oxidative 
stress and chronic low grade inflammatory process response [96]. Whether the 
wet form is a complication of dry AMD is not clear.  
 
 
Figure 5: Neovascular AMD 
 “A healthy eye without AMD (Panels A, B) has a normal retina without signs of bleeding on 
color fundus photograph (A). On optical coherence tomography (OCT) image, the anatomical 
structure of a healthy retina is intact (B). In neovascular AMD, bleeding under the retina due to 
choroidal neovascularization (blue arrows) disrupts the retinal anatomy (D) and can lead to 
hemorrhage under the macula (C) that can cause dramatic sudden loss of sharp vision.” [95] 
Pictures and description taken from [95] by courtesy of the authors. 
Risk factors  
A couple of genetic risk factors have been identified (reviewed by [81]) 
implicating that there is a heritable component in the disease. However, as the 
name foretells, various age-dependent cellular and organic dysfunctions are the 
strongest risk factors contributing to the pathogenesis of AMD. These include 
extracellular drusen formation, Bruch´s membrane stiffening (including 
increasing thickness of Bruch´s membrane and lipid accumulation), intracellular 
debris (resulting from oxidative stress-induced cell/tissue damage, lipofuscin, 
advanced glycation end products), mitochondrial defects, cell loss and tissue 
degeneration [81]. 
On the other hand several environmental and behavioral factors have been 
identified: smoking [97], history of intensive light exposure (reviewed by [81]), 
fatty, vegetable-poor diet [98] and eventually hypertension [81].  
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4. Anti-angiogenesis in tumors and other angioproliferative diseases 
Angiogenesis is essential in embryonic development and wound healing as well 
as in physiological situations such as the female reproductive cycle and the 
formation and growth of bone [10]. However not only in physiological processes 
but also in the pathogenesis of many disorders, vasculogenesis as an 
unwanted phenomenon was found to play a major role. Some examples are 
tumors, rheumatoid arthritis, psoriasis but also proliferative retinopathies, age-
related macular degeneration and several kidney diseases. 
 
Folkman et al. proposed in 1971 a hypothesis that tumor growth is 
angiogenesis-dependent [99]. Consequently, he propagated that the inhibition 
of angiogenesis was supposed to be a strategy for the treatment of solid tumors 
[100]. This strategy is based on the assumption that without the growth of new 
vessels, tumor growth will suspend and metastases will not arise (reviewed by 
[101]) . Before it was thought that the growth of new blood vessels around 
tumors was an inflammatory response, a side product of tumor growth without 
any therapeutic consequences. The following experiments and new insights 
revolutionized cancer therapy.  
By the late 1980s, suppression of tumor growth by anti-angiogenic therapy in 
mice was shown for breast and lung carcinomas and that metastases remain in 
a microscopic dormant and avascular state [102, 103]. After these 
achievements, anti-angiogenic agents quickly encroached on cancer therapy as 
supplement to conventional cytotoxic chemotherapy [104]. It was referred to 
antiangiogenic chemotherapy, low-dose chemotherapy, or metronomic 
chemotherapy.  
 
Besides cancer therapy, also non-neoplastic angioproliferative diseases were 
proven to be successfully when treated with anti-angiogenic agents. After 
haemangiomas in children were successfully treated [105], it was again 
Folkman who set up a new thesis that would open new ways in dermatology 
and ophthalmology (reviewed by [101]). They hypothesized that also psoriasis 
[106], rheumatoid arthritis, and ocular neovascularization could also be 
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angiogenesis-dependent and suggested that angiogenesis inhibitors developed 
for cancer therapy could possibly be used to treat non-neoplastic angiogenesis-
dependent diseases [101]. In 1992, it was again those scientists who attempted 
to extend their anti-proliferative therapy approach to ophthalmology and that 
find the molecular target for choroidal and retinal neovascularization in humans 
[107, 108] 
5. Therapy of wet AMD 
5.1. Phototherapy 
An early treatment of AMD was photocoagulation, showing efficacy in 
extrafoveal CNV lesions, but showed a high rate of recurrences (reviewed by 
[95]). In 2000, photodynamic therapy was approaved for the treatment of wet 
AMD. This two-step procedure consists of intravenously injected verteporfin that 
accumulates in CNV lesions and which is activated by a low energy visible red 
laser (689 nm). This therapy has the aim to occlude new vessels. Activation of 
verteporfin by light transfer of its energy to molecular oxygen, results in the 
formation of highly reactive singlet oxygen capable of producing direct damage 
of endothelial cells [81]. Due to limited effects on patients´vision and 
recurrences, photodynamic therapy is not used as primary or single AMD 
therapy [109]. 
5.2. Drugs 
It was expected that not only tumor patients but also patients suffering from 
angioproliferative eye diseases might benefit from anti-VEGF therapy. 
Currently, three anti-VEGF agents are in intravitreal use in ophthalmology: 
bevacizumab (Avastin®), ranibizumab (Lucentis®) and aflibercept (Eylea®) [81].  
The RNA aptamer Pegaptanib sodium (Macugen®, Eyetech Pharmaceuticals, 
New York, NY, USA) containing polyethylene glycol was the first substance that 
reached FDA approval for AMD in 2004. In contrast to other agents, it 
selectively binds only one member of VEGF-A family (VEGF165) with high 
affinity. Despite good efficiency in slowing the progression of wet AMD and also 
due to the fact that only few patients gained vision under the treatment [95], 
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clinical use has vastly ceased. 
 
In 1997, bevacizumab (Avastin®, Genentech Inc., San Francisco, CA, USA), a 
humanized full length anti-VEGF monoclonal antibody was developed [110] and 
was FDA approved in 2004 for intravenous use after a randomized phase III 
study on metastatic colorectal corcinoma [111]. Bevacizumab targets all 
isoforms of VEGF-A family, binds with two VEGF molecules. The mechanism of 
action is similiar to ranibizumab, although the two drugs differ in size, 
pharmacokinetics, and cost [95]. It was tested for intravitreal use in wet AMD in 
2005 and showed good efficiency. In 2006, bevacizumab led to an increased 
visual acuity in patients with neovacular age-related macular degeneration and 
is until today used on an “off-label” basis in ophthalmology [112]. 
 
Ranibizumab (Lucentis®, Genentech Inc., San Francisco, CA, USA) is a 
recombinant humanized monoclonal antibody fragment (a modified fragment of 
bevacizumab) that inhibits all isoforms of VEGF-A and binds only one VEGF 
molecule [81]. It binds to a location on the VEGF molecule that is required for 
VEGF to bind to its receptor on the surface of blood vessel cells [95]. After 
positive results in two phase-III, randomized, controlled, two-year, multicenter 
studies (MARINA [113] and ANCHOR [114]), Lucentis® was FDA- approved for 
wet AMD in 2006. One intravitreous injection contains 0.5 mg ranibizumab in 50 
µL volume. 
 
Aflibercept (Eylea®/ VEGF- Trap/ VEGF-Trap-Eye, Regeneron, Tarrytown, NY, 
USA) is a soluble fusion protein. It contains fragments of two types of VEGF 
receptors, VEGFR-1 (domain 2) and VEGFR-2 (domain 3), linked with the Fc 
fragment of human immunoglobulin G (IgG) [81]. It binds all members of VEGF-
A family (with a greater affinity than that of bevacizumab or ranibizumab), 
VEGF-B and PlGF and acts as a soluable decay receptor [81]. It was registered 
for wet AMD in 2011/2012 after having proven to be as efficient as ranibizumab 
and bevacizumab in two large clinical trial studies (VIEW 1 and VIEW 2 [115]). 
One intravitreous dose of Eylea® contains 2 mg aflibercept (50 µL).  
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5.3. Results of wet AMD therapy 
The primary aim in wet AMD therapy is the reduction of the visual loss. The 
success of the therapy is hardly predictable as it depends on a variety of factors 
including patient's age, lesion characteristics, lesion duration, baseline visual 
acuity and the presence of particular genotype risk alleles [116]. In the definition 
of patient´s response, resolution of fluid (intraretinal fluid, subretinal fluid and 
retinal thickening), improvement of letters (with the important landmark of +5 
letters), the amount of reduction from the baseline in the central retinal 
thickness [116] are tested.  
Overall, antiangiogenic therapy in wet AMD can provide vision maintenance in 
over 90% and significant improvement in 25-40% of patients [44]. In order to 
reduce the re-treatment frequency and to maintain the treatment benefit, 
occlusive therapies like photodynamic therapy can be combined [44]. 
6. Therapy of other ocular diseases with anti-VEGF agents 
Recent research has established the role of vascular endothelial growth factor 
(VEGF) as a key mediator of retinal angiogenesis and vascular permeability in 
ocular neovascular conditions other than wet AMD. These diseases and thus 
potential fields of application of anti-VEGF agents include diabetic macular 
oedema or retinal vein occlusion [117], glaucoma [118], iris rubosis [119] and 
others [120, 121]. 
7. Side effects of anti-VEGF therapy 
7.1. Side effects of systemic therapy 
Systemic anti-VEGF therapy is widely used in cancer treatment and improves 
the outcome of patients dramatically. Besides, tyrosine kinase inhibitors that 
inhibit VEGF receptors can also target the VEGF family of cytokines. However, 
as with every drug, side effects may occur. In systemic antiangiogenic therapy 
the most common are: fatigue and oral toxicity, later skin toxicity and less 
frequent hypothyroidism [122]. 
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Side effects in the kidney 
Adverse side effects concerning the kidney were observed during systemic 
antiangiogenic therapy. A frequent side effect is kidney toxicity. In particular, 
asymptomatic albuminuria/ proteinuria (but rarely nephrotic) is a common side 
effect [123]. It is dose-dependent and can result in severe glomerular damage 
by inducing down-expression or suppression of nephrin, an important protein for 
the maintenance of the glomerular slit diaphragm, sometimes leading to 
nephritic syndrome and/or renal/ glomerular thrombotic microangiopathy 
(TMA) [67, 123]. TMA is a common risk, found in bevacizumab [67, 124] and 
aflibercept [125] treated patients. Thus, a cohort study was performed and it 
was assumed that TMA and podocytopathies are a risk for all anti-VEGF agents 
[126]. Histological lesions were seen even when patients were asymptomatic 
and VEGF-down regulation in glomeruli was found. For all anti-VEGF agents 
used in cancer therapy, the incidence of mild and asymptomatic proteinuria 
ranges from 21% up to 63%, but heavy proteinuria has been reported in up to 
6.5% of renal cell carcinoma patients [123]. Moreover, proliferative 
glomerulopathies, and focal segmental glomerulosclerosis have been reported 
[68]. 
The incidence and severity of hypertension in anti-angioproliferative therapy is 
related not only to the type of the drug used, dose of the drug and dosing 
schedule, but also to the age of the patients, pre-existing hypertension and 
coexisting cardiovascular disease [41]. Proteinuria and hypertension partly led 
to drug discontinuation or counteractions like antihypertensive agents [68]. In 
the worst case, nephrotic syndrome or acute renal failure can occur and blood 
pressure and proteinuria surveillance and renal biopsies were suggested to 
decide whether the continuation of the treatment is safe [126]. The mechanism 
as to how VEGF inhibition causes renal pathologies is unclear. There are 
indications that a certain VEGF level in the glomerulus is vital to maintain 
kidney function as anti-VEGF agents seem to be toxic for the glomerular 
filtration barrier [127]. Findings by other authors that anti-VEGF agents may 
have an effect on the expression of slit diaphragm proteins [126] confirmed this 
presumption. It was also shown that inhibition of podocyte VEGF receptors may 
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result in decreased podocyte survival [128]. Although not yet completely 
revealed, this pathologic mechanism should not be a surprise, as these findings 
(hypertension and thrombotic microangiopathy) are similar to the known 
pathology of preeclampsia, in which expression of the soluble form of the VEGF 
receptor (sFLT1) increases and circulating VEGF decreases [126, 129]. 
Transmission electron micrography 
In glomeruli of patients with bevacizumab-induced TMA Izzedine et al. found, 
major alterations in TMA glomeruli, including duplication of glomerular 
basement membrane, loss of fenestrations, detachment of endothelial cells 
from original basement membrane (endotheliosis), interposition of cells, and 
marked effacement of visceral epithelial cell foot processes in some areas. 
Some podocytes exhibited cytoplasm vacuolization, as well as endoplasmic 
reticulum enlargement and mitochondrial swelling, suggesting an underlying 
apoptotic process [68, 130]. Vigneau et al. found electron microscopic 
abnormalities in patients with TMA lesions: 
Microangiopathic lesions with swelling of the endothelium as well as 
mesangiolysis were occcasionally seen [126]. Also, they saw subendothelial 
accumulation of electron lucent material in some of the capillaries and doubling 
of the capillary basement membrane [126]. 
7.2. Side effects of intravitreal therapy 
Local side effects in the eye  
Most research concerning local side effects of intravitreal anti-VEGF therapy in 
wet AMD have been performed for bevacizumab as it has always been and is 
still used in an off-label mode and as safety studies are thus necessary to 
increase clinical safety. Preclinical studies carried out on monkeys show that 
repeated anti-VEGF therapy strongly reduced the diameter of the 
choriocapillaries [131] and it was shown that bevacizumab reduced the 
diameter of retinal capillaries in patients with AMD [132]. This may result in 
atrophy of RPE-photoreceptor complex of the macula and was also found to 
correlate strongly with poor visual outcome [133]. Bevacizumab was shown to 
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accumulate and form deposits on the walls of retinal veins and between red and 
white blood cells, activate thrombocytes and induce retinal vein thrombosis and 
might result in alterations of retinal blood flow [131]. In a previous study, our 
group showed that choriocapillaris endothelial cell fenestrations were 
significantly reduced after a single intravitreal injection of bevacizumab [86]. 
Moreover, the lumen of the choriocapillaris was regionally occluded by densely 
packed thrombocytes and even photoreceptors were damaged to some extent. 
In an-other study, our group found formation of immune complexes and 
thrombotic microangiopathy in the choriocapillaris and choroidal vessels (stasis, 
swelling of the endothelium, loss of fenestrations and complete collapse of the 
capillaries) [134]. Other authors found retinal artery occlusion caused by 
bevacizumab [135] as well as a reduction of the central retinal artery velocity 7 
days after injection [136] 
Independently of the drug, the intravitreal injection itself carries a certain risk of 
local side effects. Several studies show that multiple injections can lead to 
retinal thinning and geographic atrophy (reviewed by [137]). Sigford et al. 
reviewed the endophthalmitis occurrence following the intravitreal injection of 
the anti-VEGF agents ranibizumab and bevacizumab (0.029% versus 0.058%) 
[116]. This can be considered as a risk of the surgery rather than an adverse 
effect of the drug itself. Ocular inflammation and increased intraocular pressure 
[138] as well as cataract formation, hemorrhage and retinal detachment [137] 
are reported as further local risks after intravitreal injection.  
Possible systemic side effects 
The possibility that intravitreally injected anti-VEGF agents might escape from 
the eye and reach systemic circulation is widely accepted. Penetration of these 
drugs through the retina was demonstrated, and also that the Fc receptor could 
facilitate transport of antibodies from the vitreous across the retinal 
vasculature's endothelium into the circulation [139-141]. 
The second question that has to be answered in this field is whether the small 
doses used in ophthalmology have an effect on systemic VEGF concentration 
and if this potential VEGF reduction might have systemic side effects.  
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Several groups have proven that intravitreally injected anti-VEGF agents reach 
systemic circulation and do reduce systemic VEGF concentrations (reviewed by 
[141]). Reduction in plasma VEGF levels one day, one week and one month 
after bevacizumab injection was found [142]. In other studies, effects of different 
anti-VEGF agents were compared. In a prospective series of AMD patients, the 
effects of intravitreal bevacizumab and ranibizumab on plasma VEGF were 
compared with the result that VEGF levels were much lower in bevacizumab 
than in ranibizumab treated patients [143]. IVAN [144] was the largest study to 
date to measure serum VEGF levels in AMD. The authors found a reduction of 
69% for bevacizumab and 20% for ranibizumab at 1 year, and a reduction of 
78% for bevacizumab and 28% for ranibizumab at 2 years [141]. Despite the 
variation in absolute VEGF levels between studies, the recurrent finding is that 
bevacizumab lowers systemic VEGF levels much more than ranibizumab [141]. 
For aflibercept, there is not yet much evidence in this field of research. The 
differences between ranibizumab and aflibercept can be explained by the 
differences in their molecular structure (with or without Fc fragment that is 
responsible for the recycling of a molecule and thus its half-life). Therefore, it 
can be assumed that due to its high VEGF-binding affinity and the fact that it 
contains an Fc fragment, aflibercept also significantly reduces VEGF plasma 
levels. Avery et al. measured the systemic exposure after the third monthly 
intravitreal injection to be 13-fold greater for aflibercept than ranibizumab and 
70-fold greater for bevacizumab than ranibizumab [141]. In summary, the 
systemic effect of ranibizumab appears to be the lowest, consistent with 
pharmacological differences between the agents [141]. 
8. Aim of the study  
The aim of my thesis was to evaluate possible side-effects of the two anti-VEGF 
agents aflibercept and ranibizumab when intravitreally injected in monkey eyes. 
In one study I contributed, the ciliary body and the iris were investigated as 
these two ocular components have only rarely been more closey evaluated. 
Due to their localization, they are reached by anti-VEGF agents that are 
intravitreally applied for the therapy of wet AMD. Moreover, they also contain 
I) Introduction and scientific issue  30 
 
 
 
VEGF-dependent endothelium and there are also pathologic states in which 
these tissues benefit from antiangiogenetic therapy- in neovascular glaucoma, 
for example. In addition to the examination of local effects in the eye, possible 
systemic side-effects should also be considered. This work was the main topic 
of my thesis. Given the possibility of penetration of the drugs through the retina 
and reducing systemic VEGF concentration, other organ systems could be 
influenced. The kidneys are of special interest as- similar to the choriocapillaris 
and ciliary body - their glomerular endothelium is fenestrated and the number of 
fenestrae is strongly VEGF-dependent. Counting of fenestrae in glomeruli was 
performed using a systematic uniform random sampling protocol (similar to 
[145]) to obtain a random and objective counting character and analysis. For 
these studies, monkeys were chosen as antibody molecules and their 
interaction with Fc receptor mimic those present in humans and monkey eyes 
are also more closely related to the human pathophysiology than rat or mouse 
[146]. Transmission electron microscopy is not widespread in research and the 
clinic as it demands specialized personnel and is very technically sensitive. 
Consequently,, only a few people are able to interpret the findings. However, it 
offers unique possibilities in analyzing the histology and also pathology of 
diseases and was especially indispensable for the quantification of fenestrated 
endothelia in my study, as it is required to image these sub-100-nm structures. 
My scientific issue was mainly focused on kidney histology and pathology. To 
this aim, I performed light and electron microscopic studies (including SURS 
protocol and MIA= multiple image arrays) and quantification of glomerular 
endothelial fenestrations. Moreover, I compared the findings I obtained in the 
kidney with those obtained in the ciliary body and iris as well as with earlier 
results from the retina performed by the group of Prof. Schraermeyer  and other 
researchers [86, 131, 134, 147-151]. Moreover, I performed extensive literature 
studies in order to be able to discuss the results I obtained. During my 
graduation, our group published two international peer-reviewed journal articles 
[42, 148, 150] in which I was twice co-first author. In addition, my findings were 
presented as a poster at the biggest annual meeting (ARVO) for Research in 
Vision and Ophthalmology in Orlando in USA  in 2014 [152].  
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II)  Material and Methods 
1. Animals 
„Ten cynomolgus monkeys (Macaca fascicularis, aged 3 to 8 years) were raised 
at the Covance Laboratories (Muenster, Germany) under standard conditions.” 
[42, 148] „The monkeys in this study were an average of 5.5 years old for the 
aflibercept group, and an average of 6.5 years old for the ranibizumab group.“ 
[150] ”All animals were housed and handled in strict accordance with good 
animal practice under supervision of veterinarians in accordance with the 
German Animal Welfare Act and were monitored for evidence of disease and 
changes in attitude, appetite or behaviour suggestive of illness.” [42, 148, 150]” 
“The naive Cynomolgus fascicularis monkeys are from a closed breeding 
colony (Noveprim Mauritius). Tests for TB, B-Virus, SIV, SRV, STLV, are 
carried out during export and import quarantine. Additionally tests for TB, B-
Virus, SIV, SRV, STLV are carried out regularly for all animals on site 
regardless if they are in studies or not. Cynomogus monkeys are housed in 
social groups before and during studies. The space requirements are according 
to the EU directive (DIRECTIVE 2010/63/EU OF THE EUROPEAN 
PARLIAMENT AND OF THE COUNCIL of 22 September 2010 on the 
protection of animals used for scientific purposes). The animal live under a 12-
hour dark light cycle, have ad libidum access to water and food provided twice 
daily, lab diet plus fresh fruit. The foremost enrichment is social housing. 
Additionally mirrors, wooden trunks, balls are supplied as a standard. Further 
enrichment devices are available and made available on a rotating scheme. 
The animal welfare officer on site regularly checks the housing and handling 
conditions. Since animals are housed in groups during the study the individuals 
are not randomized to the dose group, but rather a stable group of animals 
created a long time before the study.” [42] 
“For the notice of approval by the appropriate institutional animal care and use 
committee, please see Covance Studies 8260977 and 8274007.”[42, 148] For 
the ethical statement see our publication [42]. 
On days one and seven after intravitreal injection, „the animals were sacrificed 
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under general anesthesia, i.e., intramuscular injection of ketamine 
hydrochloride followed by an intravenous sodium pentobarbitone (Lethabarb, 
Virbac, Australia) overdose. Only the further investigations: electron microscopy 
and immunohistochemistry were performed in our lab in Tuebingen. These 
investigations did not necessitate approval by an institutional review board. 
Covance Laboratories GmbH test facility is fully accredited by the AAALAC. 
This study was approved by the local IACUC, headed by Dr. Jörg Luft, and 
performed in consideration of the following recommendation: 
Commission Recommendation 2007/526/EC on guidelines for the 
accommodation and care of animals used for experimental and other scientific 
purposes (Appendix A of Convention ETS 123).“ [42] 
2. Enucleation and preparation of eye tissue samples 
Both eyes of four animals of each the aflibercept and the ranibizumab group 
were intravitreally injected with the corresponding anti-VEGF drug in the doses 
that are clinically used in humans: 2 mg of aflibercept and 0,5 mg of 
ranibizumab, respectively (also provided and recommended by the 
manufacturers in this formula [153, 154]). For this procedure, which was carried 
out in the morning, the animals were intramuscularly injected with 
medeteomidine (Domitor) and slightly sedated with ketamine hydrochloride and 
diazepam. Prior to the injections, the eyes were examined for any signs of 
inflammation. [42, 148, 150] Then, „pupils were dilated (Mydriasis with 1% 
tropicamide) and anaesthetised (proxymetacaine; Proparakain-pos 0.5%; 
Ursapharm). The conjunctival and corneal surface was disinfected (povidone 
iodine 10%). After sterile coating and insertion of a lid speculum, 0.5 mg 
ranibizumab or 2 mg aflibercept were injected into the vitreous cavity using a 
27-gauge canula. When removing the canula, the injection site was 
compressed with forceps to prevent reflux and a topical antibiotic (gentamicin) 
was administered. Animals were monitored for signs of inflammation until 
sacrificed.“ [148, 150] 
During the whole duration of the animal experiment, ophthalmic examinations 
were performed (figure 6). For this, „a mydriatic agent (tropicamide) and a local 
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ophthalmic anaesthetic (proxymetacaine) were instilled in the eyes of the 
sedated animals before examination.“[148]. These examinations contained 
macroscopic and slit lamp examinations, direct/indirect ophthalmoscopy  (during 
the predose phase on the day of dosing and on the day of necropsy), 
funduscopy and fluorescein angiography (FA) (once during the predose phase 
and on the day of necropsy), spectral-domain-optical coherence tomography 
(SD-OCT) (once during the predose phase directly after injection (only for 
aflibercept) and on the day of necropsy) and measurement of intraocular 
pressure (IOP) (once during the predose phase, before administration of the 
drugs, directly and 10 min after administration and on the day of necropsy).(A 
more detailed description has been published in [148]). 
After enucleation, the eyes of the treated as well as of the untreated monkeys 
were slit at the limbus and fixed in glutaraldehyde and cacodylate buffer for 
electron microscopy or into formalin for immunohistochemistry [148, 150]. 
3. Analyses of eye tissue samples 
Immunohistochemical analysis was performed to detect ranibizumab and 
aflibercept in retinal sections and in the ciliary body using a goat antiserum to 
human Fab of IgG (for ranibizumab) and a goat antihuman IgG-Fc antibody (for 
aflibercept). A secondary antibody (cy3-rabbit antigoat antibody) was needed as 
well as further primary and secondary antibodies to also detect immune 
reactivity of astrocytes and activated and non-activated Mueller cells, 
macrophages and microglia and a hypoxia marker. “Stained sections were 
embedded and inspected with a fluorescence microscope (Axioplan2; Carl 
Zeiss, Oberkochen, Germany).“[148] (For more details see [148] and [150]). 
Specimens were prepared for light and electron microscopy following standard 
procedures (described below). Four different regions per time point were 
examined: fovea and lateral of the fovea [150] and ciliary body and iris [150]. 
The areas occupied by the choriocapillaris and free haemoglobin    were 
quantified. Moreover, quantification of choriocapillaris endothelial cell 
fenestrations and measurement of endothelial thickness  were performed and 
statistically evaluated (for details see [150]). In another study [150] endothelial 
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fenestrations of the ciliary body were quantified. Then VEGF was 
immunohistochemically localized in the ciliary body. For this, “a monoclonal 
mouse anti-human vascular endothelial growth factor, Clone VG1, which labels 
the VEGF-165, VEGF-121, and VEGF-189 isoforms of vascular endothelial 
growth factor […] was used as a first antibody  and detected with (a) […] 
detection system […] and inspected with a light microscope (Axioskop; Carl 
Zeiss, Oberkochen, Germany).“ [150]. These VEGF stainings in the ciliary body 
were photographed and semi-quantitatively investigated using a light 
microscope with AxioVision software and the „colour cube based“ function in 
the Image-Pro Plus software.  [150] For quantification of endothelial 
fenestrations of the vessels of the ciliary body, whole blood vessels were 
investigated and endothelial length was measured and fenestrations were 
counted, the ratio fenestrations/10 µm
was calculated and statistically analyzed (details in [150]). 
 
Figure 6: Overview of ophthalmic examinations performed and time points.  
Figure used with kind permission of Sylvie Julien-Schraermeyer and Ulrich Schraermeyer, first 
presented at the Novartis Meeting, November 2012. 
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4. Preparation of kidney and blood samples  
Two animals per time point and drug were available as well as one untreated 
monkey sacrificed on day seven and one monkey injected with aflibercept's 
vehicle and sacrificed one day after injection that served as controls. The 
untreated monkey showed aplasia of the left kidney. „On days one and seven 
after intravitreal injection, the animals were sacrificed under general 
anaesthesia, i.e., intramuscular injection of ketamine hydrochloride followed by 
an intravenous sodium pentobarbitone (Lethabarb, Virbac, Australia) overdose.“ 
[42, 148, 150] „The kidneys were extracted five minutes post-mortem. The left 
kidney of each animal was fixed in paraformaldehyde uncut for 
immunohistochemistry; a specimen of the right kidneys was dissected into small 
cube-like pieces with a length of 2–3 mm and then fixed in glutaraldehyde (ice 
cooled) for electron microscopy (the only available kidney of the monkey 
described above was prepared for electron microscopy). The kidneys of the 
monkey without treatment, or with aflibercept's vehicle injection, were handled 
in the same manner.“[42] “Blood samples were taken before injection (predose) 
and on days one and seven after injection. Platelet-poor plasma was prepared 
by centrifugation. “[42]. EDTA tubes prevented blood clotting.  
5. VEGF-A plasma levels 
„Blood samples of all monkeys were collected in tubes containing EDTA before 
intravitreal injection (predose) and on day one and seven after injection of anti-
VEGF agents, and plasma was prepared by centrifugation, transferred to new 
tubes and stored at −70 C. Plasma samples were analyzed using commercially 
available ELISA kits for human VEGF-A (DVE00) (R&D Systems, Minneapolis, 
Minnesota). Briefly, the microtitration plates were coated with monoclonal 
antibodies specific for VEGF-A, standards and probes were added, incubated 
and washed. Then, an enzyme-linked polyclonal antibody specific for VEGF-A 
was added and its substrate solution followed after a second incubation and 
wash step. After stopping the colour development, the intensity of colour 
(Optical Density) was measured by photospectrometry with the lower detection 
limit of VEGF-A set at 30 pg/ml. Calculation of VEGF concentration was 
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performed according to the manufacturer's recommendations.“[42] 
This kit uses human VEGF-A specific antibodies and an enzyme-linked 
polyclonal antibody specific for human VEGF-A and a substrate solution 
employing the quantitative sandwich enzyme immunoassay technique. Color 
develops in proportion to the amount of VEGF bound in the initial step. The 
color development is stopped and the intensity of the color (Optical Density) is 
measured by photospectrometry and VEGF concentration is calculated. The 
lower detection limit of VEGF-A of this array is 30 pg/ml (for more details please 
see [42, 155]). 
6. Immunohistochemistry of kidney samples 
(These experiments were performed by Alexander Tschulakow and described 
in [42])  
The aim of the immunohistochemichal analyses and fluorescence stainings was 
to evaluate the distribution of VEGF, aflibercept and ranibizumab in kidney 
glomeruli of treated animals and the untreated animal serving as control. 
The distribution of VEGF was evaluated using primary mouse anti-VEGF 
antibodies [42]. Also, immune reactivity against the two drugs was tested. For 
ranibizumab, a primary mouse antibody against the human IgG-Fab- fragment 
and for aflibercept a primary mouse antibody against the human IgG- Fc-
fragment were used [42].  
Additionally, using fluorescent antibodies (“a mouse antibody against the 
human IgG-Fab-fragment of IgG… and a goat anti-mouse alexa488 labeled 
secondary antibody […] were used for ranibizumab staining. Goat anti-human 
IgG-Fc antibody […].and a donkey anti-goat alexa488 labeled secondary 
antibody […] were used for aflibercept staining.“ [42]), an immune reactivity 
analysis was performed for aflibercept and ranibizumab [42]. 
The different stainings (VEGF/ ranibizumab/ aflibercept) were quantified using a 
semi- quantitative computer-assisted method [42]. For each kidney, ten 
randomly chosen regions containing glomeruli were photographed at a 
magnification of 400x using a computer software which also assisted in 
counting nuclei and determining the stained area after the glomeruli were 
II)  Material and Methods   
 
 
6
defined as the area of interest (aoi). For this purpose, several color 
deconvolution plugs, filters and algorithms for nuclei count were used as widely 
used for immunohistochemistry analysis [156],[157, 158] and pictures of the 
control samples served as references. Then, statistical analysis of the 
calculated ratio of stained area/nuclei was performed and samples were 
compared (for a more detailed description and pictures please see [42]). 
7. Light and transmission electron microscopy of kidney samples 
(Sigrid Schultheiss and Tatjana Taubitz performed the procedures described.)  
7.1. Fixation 
Organic sample material can either be fixed in formaldehyde or glutaraldehyde 
depending on the planned examination method. For common histological 
staining methods in light microscopy as well as for immunohistochemistry, 
organic samples are fixed in (para-) formaldehyde and embedded in paraffin as 
was performed for the left kidney of each animal in this study. These routine 
examination methods cannot be applied to glutaraldehyde- fixed specimens for 
electron microscopy. In this study, the fixation method for light microscopy is 
also performed with the right kidney of each animal with the aim of being able to 
assess histological features of the samples as well as to perform 
immunohistochemical analyses. Moreover, specimens are thus conserved in 
good quality for further use for a time period of one to two years [159]. 
“(Glutaraldehyde-fixed) specimens were postfixed with 1% OsO4 at room 
temperature in 0.1 M cacodylate buffer (pH 7.4), en bloc stained with uranyl 
acetate and lead citrate, and embedded in Epon after dehydration in a graded 
series of […] (ethanols)” [42, 148, 150]. More details concerning fixation, 
dehydration and embedding protocol will be described later.  
Glutaraldehyde causes cross-linking and fixation of proteins, osmiumtetroxid 
fixes and colors lipids black. Epon is necessary to make samples sliceable. The 
staining achieved with lead citrate is called “negative stain” as heavy atoms 
disperse electrons more strongly and thus enhance contrast [159]. 
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7.2. Preparation for examination and technical equipment 
“Semithin sections were stained with Toluidine Blue and examined by light 
microscopy (Zeiss Axioplan2 imaging, Zeiss, Jena, Germany). For electron 
microscopy, the sections were cut ultrathin and analyzed with a Zeiss 902 a 
electron microscope (Zeiss, Jena, Germany)” [42, 148, 150]. In the following I 
will describe these processes more explicitly.   
In figures 7-12, technical equipment needed for the preparation and 
examination of sample material including the transmission electron micrograph 
can be seen (light microscope not shown). 
 
 
 
Figure 7: Transmission Electron microscope  
Transmission Electron microscope Zeiss EM 902a with Digital camera MegaView III 
Its height is about 3 meters and it requires a dark room. 
Picture used with kind permission of Prof. Schraermeyer. 
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Figure 8: Ultramicrotom 
Ultramicrotom Ultracut Reichert-Jung and electric control device to adjust slide thickness (here 
0,7µm for semi-thin slides).  
Different diamonds are used to cut different thicknesses for light (semithin 0,7 µm) and electron 
(ultrathin 0,05 µm) microscopy under microscopic control. Slides swim on a water film and have 
to be fished for further processing. 
Own picture. 
 
 
  
Figure 9: Electron microscope and camera in use 
Live pictures are visible with the help of the camera and the monitor 
1. Tools to adjust magnification and contrast 
2. Grid coordinate display (X and Y) 
3. X and Y grid position control keys 
4. Side entry to lock in specimens into vacuum 
Own picture. 
1 
3 
2 
4 
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Figure 10: Formvar-coating and preparation of grids for TEM (1st step) 
First, glass slides are coated with the support film formar (a thermoplastic resin in 
dichlorethane) under a flue (not shown). Then the formvar layer is cut into smaller pieces with a 
razor blade and transferred to the surface of a water basin filled with aqua dest. Then empty 
aluminum grids are set in rows on these formvar layers. 
Own picture. 
 
 
 
Figure 11: Formvar-coating and preparation of grids for TEM (2nd step) 
The upper part of the grid is covered with parafilm (a plastic paraffin film), turned and 
transferred to a petri dish to dry. Then the grids are ready to be coated with the ultrathin cut 
slide. 
Own picture. 
 
We use formvar-coated one-hole grids (see figures 10+11) for electron 
microscopy to provide a larger area to examine under the microscope and take 
pictures although these grids are fragile and have to be treated with care. Other 
laboratories also use mesh, bar, slot or tabbed grids with the advantage of 
being more stable and of facilitating navigation within the sample. On the other 
hand, these grids impair the quality of the pictures obtained and probably make 
it more difficult to assess histological and pathological features. 
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Formvar is a thermoplastic resin and forms an electron-transparent film 
commonly used to support specimens for transmission electron microscopy. 
Moreover, it offers more radiation resilience but it also provides an unwanted 
background in the image [159]. 
A Reichert/ Leica UltraCut E ultramicrotome (see Figure 8) is used to cut semi-
thin (for light microscopy) and ultra-thin (for TEM) sections of resin-embedded 
biological specimens. For cutting, glass and diamond knives are used. First, the 
plastic block is clamped in the ultramicrotome, and then trimmed so that the 
sample location is optimally cut (pyramid). For semi-thin sections and ultra-thin 
sections, the slide thickness can be exactly adjusted with an electric control 
device (see Figure 8) to 0,7µm or 0,05 µm, respectively. After cutting, the 
sections float on the water and can be caught with an eyelet to be further 
processed for light microscopy. For electron microscopic processing, a grid has 
to be placed angularly under the floating section so that the section is attached 
when the grid is slowly pulled out of the water.  
It should be noted that these procedures have to be performed under 
microscopic control. 
 
 
Figure 12: Ultramicrotome  
 
After trimming of the block (pyramid), a semi-thin slide (0,7ym) has been cut with the 
ultramicrotome (Reichert/ Leica UltraCut E) using a diamond knife and is being captured from 
the water surface with an eyelet to be transferred to a glass slide to dry before staining with 
Toluidine Blue for light microscopy (see below). 
Ultramicrotome (Reichert/ Leica UltraCut E); Own picture. 
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For transmission electron microscopy, slides are cut ultrathin (0,05 µm). For 
staining with lead citrate, the ultrathin slide has to be captured with a formvar-
coated grid and dried (process not shown).  
7.3. Staining 
Toluidine Blue staining for light microscopy 
Toluidine Blue (0,5% Toluidine Blue with 2,5% NaHCO3 1:1) stains membranes 
and nuclei (Figures 13-15). Light microscopy allows better orientation within the 
sample and excludes pathologies.  
 
 
Figure 13: Toluidine Blue staining of kidney specimens for light microscopy (1st 
step) 
The slide captured from the water basin of the ultramicrotome (see figure 12) is set on a drop of 
aqua dest on a glass slide. 
Own picture. 
 
 
 
Figure 14: Toluidine Blue staining of kidney specimens for light microscopy (2nd 
step) 
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After the water has evaporated at 80°C, a drop of Toluidine Blue mixture (0,5% Toluidine Blue 
with 2,5% NaHCO3 1:1) is applied for 1 minute, then first rinsed with water, then with aqua dest. 
In the following it is covered with one drop of epon and kept at 60°C overnight. 
Own picture. 
 
 
Figure 15: Toluidine Blue staining of kidney specimens for light microscopy (3rd 
step) 
The semi-thin slides on glass slides ready for light microscopy. Here Lucentis (ranibizumab) 
days 7 and 1. Numbers from top to bottom: Block number, specimen: medicament, day and 
organ, slide number, date of preparation of slide. 
Own picture. 
Lead citrate staining for transmission electron microscopy 
Post-staining of sections is optional in electron microscopy (Figures 16-17). The 
indication depends on the purpose of the analysis. If the aim is mainly to take 
qualitatively good pictures and perform ultrastructural analyses or counting of 
fenestrations as in my case, contrasting with heavy metal ions is useful to 
represent the structures (membranes, vesicles.). But as this technique doesn´t 
allow antigen-antibody binding it cannot be applied in immunohistochemistry 
[159]. 
The grid loaded with the ultra-thin slide captured from the water basin of the 
ultramicrotome (see figure 12) is first dried for at least one hour. Then, it is 
placed on a drop of lead citrate ((0,1g/ 25ml+ NaOH) on a parafilm. After this, 
the sections have to dry again for 24 hours. The described procedures of 
fixation, cutting and staining are concluded in figure 18. 
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Figure 16: Lead citrate post-staining for transmission electron microscopy (1st 
step)  
Own picture. 
 
 
 
Figure 17: Lead citrate poststaining for transmission electron microscopy (2nd 
step) 
Own picture. 
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Figure 18: Preparation of glutaraldehyde fixed specimens for light and electron 
microscopy  
The figure shows the procedures as performed in the laboratory of the eye hospital Tübingen at 
the time of preparation of the kidney samples for this study. 
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*For details of Toluidine Blue staining see figures 13-15 
**For details of filming of the one-hole grids with the help of formvar- films before staining with 
lead citrate see figures 16-17 
Own pictures, composition and description similar to a work instruction in the section for 
experimental vitreoretinal surgery of the eye hospital Tübingen, adaption by kind permission of 
Prof. Schraermeyer 
 
7.4. Transmission electron microscopy (TEM) 
(The major source of information for the following is the script “Instructions for 
the internship Analytical Electron Microscopy for natural and life sciences“ [159] 
of Prof. Dr. O. Eibl (Institute of Applied Physics) and Prof. Dr. U. Schraermeyer 
(University Eye Hospital) edited January 27, 2014 containing information from 
the following sources: [160-171].) 
Transmission electron microscopy is an exclusive and also cost–intensive 
research method. Technically sensitive, preparation of samples is complex and 
needs specialized experienced personal. There are only a few scientific 
institutions owing and working with an electron microscope, thus studies and 
scientific issues have to be planned thoroughly and users have to work 
accurately as sample numbers are limited and very fragile (with one grid having 
a diameter of about 3mm [172]). Moreover, the time for viewing one piece of 
specimen is limited before the focused area is destroyed by the electron beam. 
But to follow up complex ultrastructural considerations it offers unique 
possibilities due to its high resolution of 0,5-0,2nm [173] and the trend is even 
higher (0,1nm) in modern devices which is in the range of the size of atoms 
[159]. 
Figure 19 shows the setup of a transmission electron microscope. 
 
“The finding that rotationally symmetric electric and magnetic fields act as 
lenses for charged particles“ [159] was the beginning of electron optics [159]. In 
electron microscopy, these lenses are used to guide high energetic electrons 
[159]. The basis of electron microscopy is the interaction of primary electrons 
with the atoms in the sample [159]. In the TEM free electrons are generated 
and accelerated to energies around 150keV [172]. Then, „an (ultrathin) 
specimen is irradiated with an electron beam of uniform current density“ [173] 
II)  Material and Methods   
 
 
16
where electrons are partly scattered. Specimens have to be cut ultrathin to 
avoid too much scattering and absorption of electrons [172].  
The microscope operates under a vacuum in order to prevent electrons from 
being additionally deflected [172]. Thus, specimens fixed on grids (see above) 
have to be locked in (side entry in our microscope see Figure 9). The electrons 
provided by a heated wolfram cathode are accelerated by a high voltage source 
[172]. They are deflected by the condenser lens system so as to provide 
illumination uniformity with the electrons hitting the specimen nearly parallelly. 
Having passed the specimen, the electrons change their direction due to 
different interactions with the atoms contained (the most important ones are: 
elastic and inelastic scattering; also: generation of x-radiation) [172]. The 
contrast of the obtained image depends on the kind of the specimen (solid, 
amorph, crystalline, metals, organic….) as electron-specimen interactions differ 
between materials due to different nuclear composition [172]. 
Elastically scattered electrons are responsible for the majority of the resulting 
contrasts. Heavy atoms scatter electrons more strongly than light ones; a higher 
density of atoms in a volume scatters more than a smaller amount of atoms in 
the same volume [159]. Two types of imaging can be distinguished: Dark-field 
image and bright field image microscopy depending on whether the beam of 
unscattered (bright field) or scattered (dark field) electrons is used to produce 
the image [159]. In the most commonly used bright-field image, heavy atoms 
and densely packed atoms appear dark. Staining with heavy metals allows 
identification of cell components in biological material [159]. Our samples are 
stained with lead citrate. 
The main lens of each electron microscope is the objective lens close to the 
specimen. The objective lens system generates an intermediate image which is 
magnified by the following lenses [159].  In the objective aperture in the back 
focal plane of the objective lens, a specific ray is manually selected for imaging 
which enhances the contrast of the image [159]. This is also called the contrast 
aperture and decides on the imaging mode depending on whether the 
transmitted beam is selected (bright-field image) or the diffracted beam is 
selected (dark-field image) [159]. 
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The projective lens system, which forms the next level, casts the first 
intermediate image generated by the objective-lens-system on a detector and 
magnifies it. This detector can be a fluorescent screen for direct observation or 
a camera (as we perform with the MegaView III camera in addition to the 
possibility of looking directly at the image). Note that all the TEM pictures shown 
in my work are bright-field camera images of lead citrate poststained samples. 
 
 
Figure 19: Schematic composition of a transmission electron microscope  
(TEM)  
Picture probably taken from manufacturer´s manual, image serving as illustrative material in the 
room used for electron microscopy, with kind permission of Prof. Schraermeyer, modified. 
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8. Quantification of the glomerular endothelial fenestrations  
“Under the light microscope at a low magnification (x10) glomeruli were 
identified in semi-thin sections and checked (for) mechanical or fixation artifacts 
and pathological features at a higher magnification. Three glomeruli per kidney 
(six per time point for ranibizumab and aflibercept, three for controls) with 
middle to large diameter and intact bowman’s capsules were chosen and cut 
ultrathin for electron microscopy. After examination of the ..(samples) at a 
magnification of 3000 fold, montages of transmission electron micrographs 
were performed by using the multiple image arrangements (MIAs) in order to 
provide montages of the entire glomeruli (figure 20). The montages consist of 
overlapping images that were taken using an image analysis software (iTEM, 
Olympus Soft Imaging Solutions, Muenster, Germany). Similarly to a previously 
described method [145], high- magnification images were taken from the 
chosen glomeruli according to a systematic uniform random sampling protocol 
(SURS). Starting at the top-most portion of the glomerular tuft, x 20.000 images 
were taken moving the position of the thin section grid with the help of the X 
and Y grid position control keys. For this purpose, the grid was moved ten units 
horizontally taking a picture at each stop point until the opposite portion of the 
capsule was reached. Then the position of the grid was moved 10 units 
vertically and 5 units to the right or left, respectively. This procedure was 
continued until the entire glomerular profile was scanned through (published in 
[150], also see figure 21). After pictures were scanned through for artifacts by a 
blinded observer, high- magnification images were used for quantification of 
glomerular fenestration using a counting tool of the iTEM software. Only 
pictures on which glomerular endothelium was undoubtedly identifiable were 
analyzed. A line was drawn and measured along the lamina rara interna of the 
endothelial basement membrane adjacent to the fenestrated endothelium and 
fenestrations were counted by a single observer under standardized conditions. 
As capillary walls can be divided into peripheral and mesangial regions [145], 
only peripheral portions where glomerular basement membranes and capillary 
walls show parallelism were considered. We found that the quantification in the 
mesangial portions is not comparable to the peripheral parts as the 
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predominant amount of mesangial endothelium is not fenestrated whereas on 
the other hand there are parts with increased fenestration (as described as 
‘‘alveolus fenestratus endothelialis’’ by Kondo et al. [174]). Thus, this 
endothelium is morphologically not comparable to the single layered 
endothelium in the peripheral portions so that applying the same quantification 
method would not be admissible (published in [150] , see also figure 23 A+B). 
Therefore, the mesangial portions were excluded from the quantification of the 
fenestrations” [42]. 
The random character of the analysis is of importance as well as the 
standardized protocol to obtain pictures of each glomerulus. This is an objective 
procedure and it regulates which parts of the capillaries are evaluated. 
Measuring the diameter/endothelial length of each capillary and counting the 
fenestrations to obtain the ratio fenestrae/µm as performed for the 
choriocapillaries in other studies (for example [150]) wouldn´t be applicable as 
glomerular capillaries are much larger than those of the choriocapillaris and as 
magnification has to be as high as 30 000 to be able to quantify the 
fenestrations. The bowman capsule can be easily identified even by 
inexperienced observers (see Figure 22) and represents the end of each line of 
the SURS protocol. The Zeiss EM 900 possesses two operation units to select 
sample areas: a trackball for fine steps and X and Y grid position control keys 
for large steps. To perform this systematic uniform random sampling protocol 
(SURS) the second mentioned operation unit is indispensible as has already 
been proposed by other authors [145]. 
With the method performed, a high number of pictures are taken in a time-
efficient way, which protects the samples from major damage and permits re-
evaluating if necessary, and the taking of the multiple image arrangements 
(MIAs) in order to provide an overview of the entire glomerulus. In order to 
maximize the chance to unequivocally identify the fenestrations of the 
endothelium, first the pictures for the counting analysis were taken, then those 
for the overlapping MIA´s. This compromise can be seen in the montage 
images (for details see figures 20-26 and Results section below). 
But the even more important aspect of the SURS analysis method performed is 
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that it is left to chance as to whether the fenestrated endothelium is captured or 
not. This feature makes the examination method observer-independent. 
Moreover, the method is reproducible even though the results obtained for a 
single specimen are not as it is technically nearly impossible that a grid is 
positioned in the grid holder of the electron microscope at the same plce twice. 
This is another point that makes it necessary to perform all planned 
examination methods at one time on one grid. 
MIA´s have to be performed to get a good overview of the examined 
glomerulus. With one glomerulus having a size of about 200 µm [51], the low 
magnification necessary to capture the whole structure would reach the limits of 
what is possible with a transmission electron microscope. Moreover, 
overlapping pictures as performed with the MIA´s offer a much higher resolution 
and thus make it possible to assess possible pathologies. 
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Figure 20: Example of a MIA 
„Example of a montage of transmission electron micrographs by using multiple image 
arrangements (MIAs) in order to provide the entire renal glomerulus. These images were taken 
using the image analysis software iTEM at the magnification of 63000. Here one day after 
aflibercept injection“ [42] Note also the proximal and distal tubules and collecting tubules/ ducts 
can be seen.  
Own image, figure and legend published in [42]. 
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Figure 21: Demonstration of the SURS method on a MIA  
“Demonstration of the systematic uniform random sampling protocol (SURS) on a multiple 
image arrangement (MIA). Transmission electron microscopy, magnification ×3000. Sample: 
Aflibercept day 1, Glomerulus 1. Asterisk marks starting position (first picture), double asterisks 
mark end position (last picture), arrows mark direction into which SURS was performed.“ [42]  
Own image, figure and legend published in [42], modified. 
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Figure 22: Recognition of Bowman capsule during SURS protocol 
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The images were taken performing the SURS protocol in glomeruli of Aflibercept day 7, images 
are uncut. The shown images mark stop points of rows performed in x-direction before moving 
the grid vertically in y-direction. Once having identified the glomerulus at low magnification (not 
shown), certain ultrastructural characteristics make it easy to identify Bowman´s capsule even 
for inexperienced observers in spite of the small image section seen at this magnification of 
x20000: 
 - the parietal layer of Bowman's capsule (arrows) is easy recognizable. In most cases, 
either pericarya or nuclei can be seen. Note that parietal cells exhibit a cilium and show 
numerous vesicles and intermediate filaments [51] (see C,D,E,F,G). They have also 
been described as “parietal podocytes” at the vascular pole of the human glomerulus by 
Gibson et al. [175] as they resemble visceral podocytes 
 - also, the urinary space/capsular space (asterisks) separating the parietal and visceral 
layers of Bowman's capsule can easily be seen 
 - the basement membrane of the parietal endothelial cells (PBM=Parietal basement 
membrane) is considerably thicker than the glomerular basement membrane  
 - in contrast to the GBM (consists of lamina rara interna, lamina densa, lamina rara 
externa), the PBM contains an outer lamina reticularis with a high amount of reticular 
fibers. Moreover, collagen is seen in the interstitial space below the PBM. These fibers 
are a very good marker no matter if they are cut longitudinal or transverse. As soon as 
a high amount of collagen fibers is seen close to the glomerulus, the direction of the 
SURS protocol can be changed with fibrosis being excluded by former ultrastructural 
analyses of the interesting areas 
 
If in a rare case the image does not hit Bowman´s capsule and is taken further laterally, no parts  
of the glomerulus are identifiable. Then the tubular basement membrane can be seen as the 
glomerulus is always accompanied by proximal and distal tubules. 
Own images, sample: aflibercept day 7, three different glomeruli.  
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Figure 23: TEM Example to distinguish between peripheral and mesangial 
portions 
 „Examples of representative transmission electron micrographs of (A) a fenestrated glomerular 
endothelium and of (B) peripheral versus mesangial portions of the glomerular endothelium 
(both one day after aflibercept injection). 
(A) Blood lumen on the upper part, urinary space on the lower part of the image. The healthy 
glomerular filtration barrier consists of three layers [67]: the fenestrated glomerular endothelial 
cells, the intervening glomerular basement membrane and the podocyte processes and slit 
diaphragm. GBM =  glomerular basement membrane, CL =  capillary lumen, POD =  podocyte. 
Arrows mark glomerular endothelial cells fenestrae (note the absence of diaphragm), asterisks 
mark podocyte foot processes, arrowheads mark podocyte slit diaphragm. 
(B) At this magnification, podocyte foot processes (asterisks) allow the clear identification of the 
capillary lumen (CL). In accordance with our definition, the peripheral portion begins where the 
endothelium and the glomerular endothelial basement membrane (GBM) run approximately 
parallel (marked by arrows). Arrows mark the direction into which the peripheral endothelium 
begins. In between the arrows the mesangium (Mes) and the mesangial portion of the capillary 
endothelium (MesE) is located. Note that in the mesangial portion there is no GBM adjacent to 
the fenestrated endothelium so that the counting method described is not applicable and the 
endothelium does not show the typical single- layered configuration. Magnification ×20000.“ [42] 
Own images, figures and legends published in [42], modified. 
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Figure 24: Demonstration of the estimation of the ratio fenestrae per µm  
Demonstration of the estimation with the counting tool of the iTEM software 
The red line is manually drawn along the lamina rara interna of the endothelial basement 
membrane adjacent to the fenestrated endothelium. A single observer under standardized 
conditions counts fenestrations manually (red crosses). Here: 18 fenestrations per 9,01 µm 
endothelial length. Then the program calculates the ratio fenestrae per µm automatically and 
provides a table and a statistic. Asterisks mark primary and secondary podocyte processes, X 
marks glomerular basement membrane, e= erythrocyte, fEC and arrows= fenestrated 
endothelial cells, CL=capillary lumen, a= artifacts.  
Own image, sample: aflibercept vehicle, glomerulus 1. 
II)  Material and Methods   
 
 
27
  
Figure 25: Examples for surrounding structures of the glomerulus 
First image: Magnification/ detail image of figure 20 (bottom left part): 
Part of a proximal tubule with typical brush border (crosses) and basal infoldings (BI) with a 
high amount of mitochondria.  
Second image: Magnification/detail image of figure 20 (upper right part): 
Part of a distal tubule. Note that there is no brush border, the diameter is apparently smaller and 
the epithelium lower than in A. Also, the lumen appears larger and cell borders are better 
recognizable than in the proximal tubules. 
Note also the interstitial /connective tissue between the tubules and between tubules and 
glomerulus (G) with peritubular capillaries (C) (partly with erythrocytes) 
Own images, detail images of figure 20 (MIA), sample: Aflibercept day 1,magnification x3000. 
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Figure 26: Details of surrounding structures and Bowman´s capsule at higher 
magnification 
First image: transition zone of the glomerulus(bottom) to a proximal tubule (top). Note the 
multiple basal infolding of the basement membrane of the proximal tubule (TBM) and the high 
amount of mitochondria (asterisks). Also, parts of connective tissue (CT) and the basement 
membrane of the parietal layer of bowman´s capsule (PBM) can be seen.   
Own picture, sample: Aflibercept day 1, magnification x20 000 
Second picture: another example of the transition zone. Here, part of a glomerular capillary with 
podocyte foot processes (POD), glomerular basement membrane (GBM) and fenestrated 
endothelium (fEN) as well as a part of a prominent nucleus of an endothelial cell (nEN) can be 
seen. On the lower left part of the picture the parietal portion of Bowman´s capsule (parietal 
epithelial cell =pEC,  parietal basement membrane= PBM) and connective tissue (CT) as well 
as the basement membrane of the following structure (asterisk) can be seen. 
Own image, sample: Aflibercept day 1, magnification x20 000. 
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9. Statistical analyses of fenestrae per µm 
„The ratio of fenestrae per µm was calculated using Microsoft-Office-Excel for 
each image considered. Statistical significances for the evaluation of the 
(number of) fenestrae per µm of the glomerular capillaries and for the 
quantification of VEGF as well as ranibizumab/aflibercept were determined by 
using the Student's t test from the JMP10 statistical program (SAS, Heidelberg, 
Germany). P<0.05 was considered statistically significant.“ [42] 
The image analysis software (iTEM, Olympus Soft Imaging Solutions, Muenster, 
Germany) automatically calculates the ratio of fenestrae/µm when the analysis 
is manually performed with the counting tool. These data were exported to 
Microsoft Office Excel 2011 and to the JMP statistical program (SAS, 
Heidelberg, Germany, Versions 10 and 13). Charts were generated using JMP 
software. For descriptive statistics, common values (arithmetic means, medians, 
standard deviations, standard errors, confidence intervals) were calculated and 
distributions of values were analyzed via histograms. For statistical evaluation 
of data and especially comparison of groups, analysis of variance (ANOVA), 
Student´s t-test and Tukey Kramer HSD test were performed with the level of 
significance conventionally set at alpha =0.05. Also, power and sensitivity of the 
tests were calculated and critically regarded as well as the study design and 
sample collection and size. In the following, the applied statistical terms and 
techniques are briefly summarized.. 
One aim of statistical analysis is to estimate the population mean. For this 
purpose, different values can be calculated. The arithmetic mean is the 
average of a collection of values. It is calculated as the sum of the values 
divided by their number [176]. Another statistic that can be calculated is the 
median. The median is the one observation which divides the sample into two 
equal groups with at most half of the values falling below and at most half of the 
values above it [177]. There are two important differences between these two 
values: In a normal distribution (see below), the variance of the mean is smaller 
than the variance of the median resulting in a higher precision of the mean. On 
the other hand, the mean can be more greatly affected by outliers than the 
median [176]. 
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Variance, Standard deviation, standard error 
“Variance is the expected squared deviation of a random variable from its 
expected value […] standard deviation is the square root of the variance” [176].  
Standard error is an estimation for the standard deviation of the mean [177]. 
Box Plots 
„The box part […] surrounds the middle half of the data. The lower edge of the 
rectangle represents the lower quartile, the higher edge represents the upper 
quartile, and the line in the middle of the rectangle is the median […] the lines 
extending from the box show the tails of the distribution […] these lines are also 
sometimes called whiskers […] points farther away are shown individually as 
outliers” [176].  
Gaussian distribution  
This distribution, also called normal distribution is often applied to describe the 
dispersion of data, especially the natural variability [177]. The dispersion around 
the average value is here a consequence of a variety of independent factors 
with an additive influence on each other [177]. Also, normal distribution of 
values within a sample is the basis for mathematical terms of numerous analytic 
methods (for example analysis of variance, T-test) [176]. 
As is necessary for a qualified scientific analysis, as many factors as possible 
influencing and deranging the result were eliminated with the aim of seeing the 
influence of the only variable of interest: the injected drug. Choosing 
comparable monkeys, housing them under standardized conditions and the 
coincidental assignation to the aflibercept, ranibizumab or control group 
achieved this. In addition, the injection and examination procedures of the 
animals followed a strict protocol and were performed at the same time points.  
Concerning the preparation and analysis of the samples, they were technically 
all treated the same way following the protocol of our work group (see figure 18) 
and images were randomly taken following the SURS protocol (see figure 21) 
and analyzed following distinct criteria. 
The greater the dispersion, the flatter the distension of the bell-shaped curve 
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[177]. On its left and right, the curve asymptotically approaches the x-axis. The 
peak value of the curve is the expected value, the two points of inflection of the 
curve are located one standard deviation from the expected value [177]. 
Confidence interval  
The confidence interval is a tool to indicate how exactly the expected value can 
be estimated by the arithmetic mean. The confidence interval is computed from 
a sample and is a range which contains the expected value with a given 
probability. This probability is generally 95 % and the confidence interval thus 
as large to contain the expectation value with the probability of 95 % [177]. If 
the sample is small, the estimation of the expected value underlies high 
imprecision. Hence, the confidence interval has to be larger [177]. The smaller 
the confidence interval can be set, the more precise is the estimation of the 
expected value. 
P value 
This value is used in statistical programs like the SAS JMP statistical program 
and is used for inferential analysis.[177]. The p-value can be declared as “the 
probability of being wrong if you declare an effect being non-null” [176] or the 
“significance probability” [176]. P-values below the set alpha-level (in my case 
alpha was set 0,05 as generally accepted) reject the null hypothesis, meaning 
that the probability of having an effect is very high [176] or the probability of 
being wrong when deciding for a non-null-effect is below 5 %. In terms of 
statistics, a p value less than 0,05 is thus regarded as significant [176]. 
Analysis of variance (ANOVA) 
One method to compare means of different groups is the ANOVA analysis 
(short for: “one way analysis of variance”), with the F test as its main element. It 
is usually used when more than two groups are compared [176]. The chart of 
this analysis (see Results section) displays the group means and the 95% 
confidence intervals as diamonds [176]. If these diamonds „do not overlap, the 
groups are significantly different“ [176]. For further determination of the 
difference of the group means, an analysis of variance and a t-test have to be 
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performed. 
The analysis of variance leads to an F ratio and determines whether the 
“separate-means model” or the “grand-mean model” fits better meaning in 
which estimation of the mean (groups separately or overall mean of all the 
values) the variance is larger. If the F ratio is around 1, both means are equal. If 
the F ratio increases, the separate-means model fits better [176]. If the p-value 
associated with this test is smaller than the set alpha level (here 0,05), one can 
say that there is indeed a statistical significant difference in the means of the 
groups though without specifying about which means are different [176].  
Student´s t-test 
Student´s t-test is based on the Gaussian distribution. The more degrees of 
freedom for error (number of observations minus the number of parameters 
estimated) are added, the more precise the t-test works [176]. Additionally to 
the normal distribution, the t-test requires the two group variances to be equal. 
However, it can be used with unequal variances as well when Welch´s 
correction is applied [176]. It can either be used to test whether a mean differs 
significantly from a hypothesized value [176] or “whether the difference of two 
means is significantly different from the hypothesized value of zero” [176].  
Following general definition, the specimens in this study can be considered to 
be independent groups [176]. Student´s t-test can be applied to compare many 
means by comparing each pair when the data is unbalanced (with a different 
amount of observations in each group) [176].  
Tukey-Kramer-HSD 
For finding pairwise differences between the groups, a Tukey-Kramer-HSD 
(Honestly Significant Difference) is carried out. The method compares any two 
groups for significant mean differences while correcting the significance level for 
multiple testing. This test is supposed to decrease the possibility of committing 
a Type I error, which is likely to happen when multiple comparisons are made 
and includes a protection from falsely declaring significance [176] which is not 
included in student´s t-test. 
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Sensitivity of the test 
To make sure that non-significant results are interpreted correctly, the sensitivity 
of the test has to be evaluated. Otherwise no distinction can be named between 
an experiment having too little data to make a conclusion and an analysis 
simply not being able to detect an actual difference present between values 
[176]. The estimation of the Least Significant Number (LSN) and the Least 
Significant Value (LSV) give an indication as to “how many more observations 
would make the reported difference become significant” [176] and “how small a 
difference could the significance test in this example detect” [176].  
Power 
The term statistical power defines how probable it is that an effect is detected if 
it is there [176]. It increases with the amount of data available, the less random 
variation is present, the more sensitive the statistical method [176]. There are 
two important errors in statistics: Type I error (often represented as alpha) 
means that the null hypothesis is rejected though it is true, Type II error (often 
represented as beta) means that an existing difference is not detected [176]. 
Power is 1 minus beta or in other words: the probability of detecting a difference 
[176]. 
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III)  Results 
1. Immunohistochemistry- Ranibizumab/aflibercept fluorescence staining, 
quantification and normalization 
Apart from the weak autofluorescence of erythrocytes, no specific staining of 
glomeruli was seen in samples of the control animal with either of the two 
antibodies (against the anti-human IgG-Fc fragment or against the anti-human 
Fab fragment of IgG) used [42]. This pattern changed in samples one day after 
aflibercept injection, where “the endothelium cell layer and material within the 
capillaries of many glomeruli were highly fluorescent […] Occasionally, 
glomeruli in which only the endothelium was stained were localized close to 
others that contained high amounts of IgG-Fc reactive material within the 
capillaries […] Erythrocytes within the glomeruli were highly fluorescent […] 
”[42] Examining the samples of the monkey injected with aflibercept seven days 
after injection, less fluorescent material within the capillaries was seen and the 
fluorescence was less intense [42]. Similar observations were made with 
ranibizumab samples. “One day after ranibizumab injection, the endothelium 
cell layer and erythrocytes of most glomeruli became fluorescent after labeling 
with an antibody against the human Fab fragment of IgG  […] However, the 
specific fluorescence was nearly lost seven days after injection of ranibizumab.“ 
[42] (for figures, also see [42]). 
Then after glomeruli were defined as areas of interest (aoi) and stainings were 
quantified and normalized as described above and in [42], statistical analyses 
were performed of the obtained ratio “stained area/cell count”. T-tests 
comparing mean values of immune reactivity of the areas of interest in the 
different groups were performed. „Immune reactivity against aflibercept or 
ranibizumab was only detected in aflibercept- or ranibizumab-treated animals 
respectively and did not show any significant differences between days one and 
seven“ [42]. But the detected differences in mean values between the controls 
and the treated animals were highly significant (highly significant at the 
p<0,0001 level for t-test of aflibercept day 1 and aflibercept day 7 against 
control; highly significant at the p< 0,001 level for t-test of ranibizumab day 1 
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and ranibizumab day7 against control)[42]. The corresponding controls are 
samples of the untreated monkey, “respectively after staining with the anti-Fc-
fragment antibody for aflibercept and the anti-Fab fragment antibody for 
ranibizumab immune reactivity analysis” [42]. 
2. Immunohistochemistry- Quantification and normalization of VEGF 
staining 
Also for anti-VEGF stained samples, the ratio of stained area to counted cells 
was estimated for the glomeruli representing the aoi. T-tests comparing each 
group as well as t-tests against the untreated control were performed.  
Concerning t-test against controls, differences between the aflibercept- and 
ranibizumab-treated samples can be seen: For ranibizumab-treated animals 
(days 1 and 7), “no significant changes at any of the analyzed time points […] 
compared to the untreated control-animal samples” [42] were seen. “However, 
the stained area to cells ratio of the tissue-samples of the aflibercept-treated 
animals showed a significant decrease one day […] after treatment (p<0.05) 
and an even stronger decrease seven days […] after treatment (p<0.0001) 
compared to the untreated control-animal samples” [42]. 
Comparing mean values of the different groups, differences were significant 
comparing animals treated with the two different drugs at the same time point:  
“The levels of VEGF were found to be significantly lower in the aflibercept-
treated animals on days one (p<0.05) and seven (p<0.0001) after treatment as 
compared to the corresponding ranibizumab-treated ones” [42]. Also in 
aflibercept-treated samples only, “The decrease of the VEGF level from day 
one to day seven after treatment was also found to be significant (p<0.0001)” 
[42] (also see figures in [42]). 
In conclusion, significant differences were found between the mean values of 
the ratio stained area/cell count the following groups: Concerning aflibercept/ 
ranibizumab staining, means of samples obtained from the monkeys treated 
with both drugs and sacrificed one and seven days after injection differed 
significantly from control samples. Concerning VEGF staining, samples 
obtained from monkeys injected with aflibercept on days 1 and 7 differed 
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significantly from controls. Also, significant differences were seen between 
means of the monkeys injected with the two different drugs and sacrificed at the 
same time points (Aflibercept day 1/ Ranibizumab day 1 and Aflibercept day 7/ 
Ranibizumab day 7). Moreover, the difference between Aflibercept day 1 and 7 
was significant in contrast to the not significant difference between 
Ranibizumab days 1 and seven (please see also table 3). 
 
Table 3:  Significant differences between means of groups in staining of drugs 
and VEGF 
Analyzed with the JMP software by Alexander Tschulakov, own table 
 
 
Significant difference between group means 
Ranibizumab/ aflibercept 
staining 
 
Control Aflibercept day 1 
 Control Aflibercept day 7 
 Control Ranibizumab day 1 
 Control Ranibizumab day 7 
 
VEGF staining 
 
Control 
 
Aflibercept day 1 
 Control Aflibercept day 7 
 Aflibercept day 1 Ranibizumab day 1 
 Aflibercept day 7 Ranibizumab day 7 
 Aflibercept day 1 Aflibercept day 7 
 
3.  Measurement of VEGF-A165 plasma levels 
The detectable limit of the assay was 30 pg/ml. Our doses were below this limit 
(figure 27).  
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Figure 27: Quantification of VEGF-A165 plasma concentrations in EDTA blood 
samples 
Samples of all monkeys collected in the predose phase and on day 1 or 7, respectively. 
Quantikine ELISA human immunoassay (R&D System).  Graph shows VEGF Concentration 
versus Optical Densitiy. All of the doses were below the detectable limit of the assay. 
Figure with kind permission from Sylvie Julien-Schraermeyer, own legends. 
 
4. General examinations by light and transmission electron microscopy 
“The biopsies of all the kidneys were first studied by light microscopy and also 
by TEM with increasing magnification in order to scan the specimens on 
artifacts and pathologic features (figures 28-35). None of the glomeruli was 
sclerotic. The podocyte foot processes were well-formed and did not show 
effacement, and a continuous slit diaphragma could be observed. The 
glomerular basement membrane (GBM) was of normal thickness and did not 
show duplication in all specimens without widening of the subendothelial space 
or cellular interposition. The well-defined glomerular endothelium was flattened 
though there were slight variations in thickness without endotheliosis. In all 
samples, it was mostly adjacent to the GBM. 
The capillary loops were filled with more or less electron-dense serum. The 
III)  Results 
 
 
38 
density difference could be observed in glomeruli of all of the kidneys. “ [42] 
(see figure 28). 
For an overview, overlapping x3000 TEM pictures were taken and MIA´s were 
prepared with the iTEM software as described above. This procedure allows an 
easier comparison of the general histology of the different specimens. It should 
be noted that the program limits the possible amount of pictures to create one 
MIA. Thus, if the diameter of the glomerulus is larger or if the MIA is started too 
far in the periphery or too close to the capsule of the glomerulus, it might not fit 
completely on one arranged picture. As already mentioned, the electron beam 
might destroy or at least reduce the contrast of the ultrathin cut specimen if a 
section is viewed for more than a couple of seconds. As a good quality of the 
higher magnification pictures (x20 000) for quantification of endothelial 
fenestration must be guaranteed, there was only one attempt to obtain a MIA of 
each glomerulus. This worked very well for one glomerulus of aflibercept day 1 
(see figure 20, also published in [42]). Further examples of MIA´s can be seen 
below). 
Prof. Dr. Markus van der Giet from the Division of Nephrology at the Charité 
University Berlin checked my light and electron microscopic pictures of the 
monkey kidneys and confirmed that there are no abnormalities detectable. 
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Figure 28: Overview over semithin sections 
Sections were stained with Toluidine Blue and prepared for light microscopic examination. In 
this step regions of interest containing glomeruli with a medium to large diameter and intact 
Bowman´s capsule can be chosen and prepared for electron microscopy 
Samples: A: Aflibercept day 1, B: Aflibercept day 7, C: Aflibercept day 1, D: Aflibercept day 7, 
own images. 
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Figure 29: MIA of ranibizumab day 7 
Another overview montage image (MIA) of a kidney glomerulus (incomplete). Bowman´s 
capsule (arrows) is intact but the Bowman´s space is not uniform; capillaries are filled with 
erythrocytes, no hemolysis. Asterisks mark prominent nuclei of mesangium cells. For a more 
detailed examination and for quantification of endothelial fenestrations, high magnification  (x20 
000) was used. TEM, magnification x3000. 
This MIA is incomplete due to the large diameter of the glomerulus and the fact that the capacity 
of pictures which could be composed to one multiple image arrangement were limited by the 
program used. For quantification of glomerular endothelial fenestrations, the whole glomerulus 
was scanned through performing the SURS protocol (see above). 
Own image. 
 
 
* 
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Figure 30: MIA of untreated control 
Another example of an MIA (on top) and the 4 crude partial MIA´s of which it was manually 
composed (bottom) in Adobe Photoshop, TEM, magnification x 3000. 
In this case, the glomerulus chosen was too big for the iTEM program to produce a single MIA. 
Note the lower quality compared to the automatically produced MIA due to the contrast and size 
differences of the different components. 
Own images. 
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Figure 31: 2 MIA´s of two glomeruli of aflibercept day 7, incomplete  
Here the MIA´s were started at a position too far from the center of the glomeruli resulting in 
incomplete overviews. On the upper picture, the typical contrast reduction as well as traces of 
the previously performed attempt can be seen. Note the different width of the lumen of 
Bowman´s capsule without pathological importance. 
Both MIA´s were manually composed of two partial MIA´s each with Adobe Photoshop. TEM, 
magnification x3000. 
Own images. 
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Figure 32: MIA of a glomerulus of ranibizumab day 1 
Top: the manually composed MIA (Adobe Photoshop), TEM, magnification x3000. 
Bottom: the 3 partial MIA´s taken with the iTEM software 
Own images. 
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Figure 33: MIA of aflibercept vehicle  
Another example of an MIA (on top) and the 4 partial MIA´s of which it was manually composed 
(bottom) in Adobe Photoshop, TEM, magnification x 3000. 
Here also the quality is a bit lower than of compared arrangements due to distortions.   
Own images. 
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Figure 34: Detail of glomerular electron microscopy 
Densely packed capillary loops surrounded and held by mesangium (mesangium cells and 
extracellular matrix). Note that mesangium and endothelial cell nuclei (asterisks) are very 
prominent and that podocyte foot processes can be easily identified and are an important 
marker to identify the urinary space of the glomerulus. The capillaries lined by fenestrated 
endothelium represent the blood space. Erythrocytes do not show lysis and are only found in 
the capillaries, podocytes are well-formed, no sclerosis is seen. Glomerular basement 
membrane is of even thickness without duplications and the glomerular endothelium is flat and 
adjacent to the glomerular basement membrane. These details can be better observed in higher 
magnifications as used to quantify endothelial fenestrations (see beyond). 
US= urinary spae, CL= capillary lumen, arrowheads mark podocyte foot processes, asterisks 
mark nuclei of mesangium and endothelial cells 
TEM, magnification x3000 
Sample: Untreated, own images. 
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Figure 35: Examples of TEM used for the quantification of fenestrations 
Images to compare and verify at a higher magnification that there are not any pathologies in any 
of the samples at any time point. Here, capillary endothelium, glomerular basement membrane 
and podocyte foot processes can be better assessed and the quality of electron microscopy 
appears: even organelles can be distinguished.  
(Annotation: The scale shown in the lower right corner of each picture is 1 µm) 
Examples of transmission electron micrographs used for the quantification of the glomerular 
endothelial cells fenestrations. 
(A) after injection of the vehicle; (B) in the untreated monkey; (C) one day after injection of 
ranibizumab; (D) seven days after injection of ranibizumab; (E) one day after injection of 
aflibercept; (F) seven days after injection of aflibercept. Magnification ×20000.“ [42], 
Figures and legends (partly) published in [42], modified ;own images. 
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5. Quantification of the glomerular endothelial cells fenestrations 
Kidney samples of eight monkeys of the aflibercept and the ranibizumab group, 
respectively, taken on days one and seven after injection and one untreated 
monkey as well as one monkey treated with aflibercept´s vehicle were 
examined. The obtained values of the number of fenestrations per µm of each 
group were statistically analyzed. 
Note that for simplification, values obtained from the kidneys of the different monkeys will be 
named “groups” and addressed with the name of the group spelled with a capital letter (e.g. 
“Untreated” for the group of values obtained from the untreated monkey, “Aflibercept day 1” for 
the group of values obtained from the two monkeys treated with aflibercept and sacrificed on 
day 1). 
5.1. Descriptive graphs and statistics 
Table 3 shows important statistical values of this analysis. Alpha was set 0,05, 
the confidence interval (1- alpha) thus 95 percent. Also, statistics of pooled 
controls (the groups Untreated and Aflibercept Vehicle summarized) are shown. 
This will be justified below. 
 
Table 4: Statistical values of the distribution analysis of the number of 
fenestrations per µm, all values and groups separately 
N= Number of observations    MV= Mean value     
M= Median     SD= Standard deviation       
SE = Standard error of mean value  
Calculated with SAS JMP 13. 
 
 N MV M SD SE 
All 1382 1,332 1,26 0,741 0,020 
Untreated 117 1,317 1,25 0,684 0,063 
Aflibercept 
Vehicle 
132 1,217 1,12 0,727 0,063 
Controls 
pooled 
249 1,264 1,17 0,708 0,045 
Aflibercept 
day 1 
231 1,522 1,46 0,821 0,054 
Aflibercept 
day 7 
317 1,233 1,165 0,716 0,040 
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Ranibizumab 
day 1 
297 1,324 1,28 0,671 0,039 
Ranibizumab 
day 7 
288 1,355 1,28 0,773 0,046 
 
The total number of observations is very high at 1382. The sample size of 
treated animals is higher (about double in each group) than the size of the 
single control groups (Untreated and Aflibercept Vehicle). This is due to the fact 
that there were two animals for both time points for both drugs whereas there 
were only two animals serving as controls of which one was sacrificed one day 
and the other one seven days after intravitreal injection. 
Regarding the means and medians, tendencies can be seen: The values of the 
group Aflibercept day 7 are lower than the corresponding values one day after 
injection of the drug. This trend is not seen for ranibizumab- treated samples 
where means are about equal and medians are exactly the same. One day after 
treatment, the values are by trend higher than in control samples (especially 
compared to means and median of the untreated monkey)- a tendency that is 
more distinct for Aflibercept day 1 than for Ranibizumab day 1. Also, values one 
day after injection of aflibercept are clearly higher than one day after 
ranibizumab injection. The values of the two treated groups which were 
sacrificed seven days after injection are very similar and still seem to be slightly 
higher than in control groups. The two control groups (Aflibercept Vehicle and 
Untreated) seem to be very similar concerning means and medians. Standard 
deviations and standard errors are very low in all groups. Moreover, the means 
and medians of all groups combined are very similar with corresponding values 
of the untreated monkey and also close to the values of the groups 
Ranibizumab days 1 and 7. 
The described characteristic can be visually comprehended in the following 
histograms and box plot (see figures 36 and 37) and will be further analyzed in 
the following. 
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Figure 36: Histograms of the distribution of the number of fenestrations per µm 
in the different independent groups 
The red line superimposed on the histogram represents the normal density corresponding to the 
mean and standard deviation in the sample (all observations). Also shown: distribution of values 
when control groups (Untreated and Aflibercept Vehicle) are pooled. 
The diamond shows the mean and its 95% confidence interval. The red bracket indicates the 
shortest half meaning the shortest interval containing half the data [176]. 
Software: SAS JMP 13.  
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Figure 37: Box plot representation of the quantification of the number of 
fenestrations per µm depending on the treatment and its duration, Version 1 
same groups as in figure 36. Samples of Aflibercept´s vehicle and the untreated monkey NOT 
pooled. 
Software:  SAS JMP 13. 
 
The form of the box plots also gives an indication of the existence of a normal 
distribution if there is a good parallelism of the marks and the spaces of the 
upper and lower quartiles are at about the same distance from the median 
[176]. This is approximately the case in all of the samples; the boxes also show 
good symmetry. A normal distribution of values can be assumed regarding the 
histograms in figure 36 and this is also confirmed by the illustration of the 
normal quantile plots with the JMP software, which tend to follow a straight line 
(not shown). Moreover, performing the Shapiro-Wilk Test (W statistic) to test the 
distribution for normality shows no significance in any of the groups indicating 
that the distributions are all close to normal (not shown). 
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5.2. Pooling of control samples 
As already mentioned, sample sizes of treated animals are clearly higher due to 
the double amount of animals per time point for treated animals compared to 
the two animals serving as controls for both time points. For statistical analyses, 
equal sample sizes are advantageous, thus approaching a so-called balanced 
data design [176]. 
Thus, equalizing of sample sizes has to be considered by uniting data obtained 
from the untreated monkey and the monkey treated with aflibercept´s vehicle. 
For medical reasons, this consideration can be justified. Injection of a saline 
solution may induce stress in the treated animal and may have influence on the 
treated eye, but not have any influence on the kidney. This assumption is 
supported by the obtained values in table 3 and by the fact that my 
morphological observations revealed no differences between the kidneys of 
these two monkeys. As a condition for pooling of the two samples, there must 
not be a significant difference when comparing means. The performed t-test for 
independent samples resulted in t=1,1117 and a p-value of p=0.265. There is 
thus no significant difference between these two groups. 
The sensitivity and power analysis of this t-test shows that a difference of 0,177 
(LSV= least significant value) would have been needed to be measured in order 
to detect a significant difference at an alpha level of 0,05, whereas the actual 
measured difference in the mean of the number of fenestrations per µm was 
1,317- 1,217= 0,1. The actual sample size of these two groups was 249, the 
least significant number is 774, meaning that with the given variances and 
differences, a sample size of 774 would be necessary to detect a significant 
difference (at a probability level of at least 50 % [176]). 
In conclusion, no significant difference between group means was seen and as 
this is also plausible as regards content,  observations obtained from the two 
samples Untreated and Aflibercept Vehicle were pooled. Figure 38 shows the 
box plot similar to figure 37 with the newly formed control group and 
approximately equalized sample sizes. 
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5.3. Statistical analysis comparing group means, controls pooled 
 
 
Figure 38: Box plot representation of the quantification of the number of 
fenestrations per µm depending on the treatment and its duration, Version 2 
Samples of the monkey treated with aflibercept´s vehicle and the untreated monkey pooled. 
Software:  SAS JMP 13. 
 
The visual analysis of this box plot shows the following trends of which most are 
comparable to those seen in figure 37: a higher mean of the group Aflibercept 
day 1 compared to all the other groups including the group Control. Also the 
decrease from day 1 after treatment to day 7 is seen, which is clearly more 
distinct for the aflibercept-treated samples. Comparing the two groups injected 
with the different drugs and sacrificed at the same time points, the means of the 
aflibercept-treated samples seem to be higher than those of the ranibizumab-
treated groups one day after injection and means seem to be about equal 
seven days after injection of the two drugs. Comparing mean values of the 
groups seven days after injection of ranibizumab and the group mean of the 
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control, roughly no difference is visually recognizable. 
The form of the newly formed box plot of the group Control is comparable to 
those of the groups Aflibercept Vehicle and Untreated in figure 37 with very 
good symmetry. 
One way ANOVA analysis of number of fenestrations/ µm versus 
specimen, analysis of variance 
To estimate if the group means of the five independent samples differ 
significantly, a one way ANOVA analysis of the ratio number of fenestrations/ 
µm was performed. The preconditions for this analysis are: the existence of a 
Gaussian distribution in all samples and the homogeneity of variance in all 
samples [176]. The fulfillment of these conditions can be assumed as there are 
no big differences in the standard deviations (see table 3) and as the visual 
assessment of the histograms in figure 36 as well as the W statistics indicate a 
normal distribution of values with values roughly in the range between 0 and 4. 
The chart of the ANOVA analysis can be seen in figure 39. F=5,911, the 
corresponding p-value is highly significant with p= 0,0001. This indicates that 
there is indeed a statistically significant difference between the group means, 
but which groups differ is not specified in this analysis. Thus, to further 
investigate these differences, multiple comparisons performing the Tukey-
Kramer-HSD test have to be made. The results can be seen in figure 40. 
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Figure 39: One-way ANOVA analysis 
Chart of the one-way ANOVA analysis to estimate differences between the mean values of 
groups. Each group is formed by the values of the number of fenestrations per µm of two 
monkeys, the groups Untreated and Aflibercept Vehicle are pooled as “Control”. 
The diamonds represent the 95% confidence interval around the group means (center lines of 
the diamonds), “The line across the middle is at the grand mean” [176]. 
Also note the similar sample size illustrated by the distance the diamonds cover along the x 
axis. 
software: SAS JMP 13. 
 
 
Figure 40: Sorted list of differences between the means of the groups, Tukey-
Kramer-HSD test  
The groups Untreated and Aflibercept Vehicle are pooled as “Control”. Note that only 
differences between the first 2 couples are significant at an alpha level of 0,05. The value in the 
middle of the table marked red is on the edge of being significant. 
Software: SAS JMP 13, German. 
 
The one-way ANOVA analysis shows that the confidence intervals of some of 
the different groups shown by the diamonds in the chart (figure 39) do not 
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95% confidence interval of the group Aflibercept day 1 does not overlap with the 
confidence interval of the groups Aflibercept day 7, Control and Ranibizumab 
day 1. This assumption has to be further followed. On the other hand, all the 
other confidence intervals do overlap. Thus, it has to be evaluated to which 
extent these means are different with the help of the p values and analyses of 
variance. .As the F ratio with 5,911 is considerably larger than 1, the analysis of 
variance reveals that the separate-means model of the different groups fits 
better than the one-mean model summarizing the mean of all the values [176]. 
This fact together with the p-value associated with the F ratio in the analysis of 
variance that is smaller than 0,05 (p <0,0001, highly significant) leads to the 
conclusion that “the variance around the group mean is (highly) significantly 
less than the variance around the grand mean” [176]. Thus, there is indeed a 
difference between the group means; the groups do differ but it is not yet known 
which means are different. 
To find out more about the differences between the means of the particular 
groups, student´s t- test comparing each pair can be performed. But as already 
mentioned, the Tukey-Kramer-HSD test is more effective in preventing false 
declarations of significant differences than the t-test and is thus more suitable 
for performing multiple comparisons [176]. The list of sorted differences of the 
Tukey-Kramer-HSD test (see figure 40) indicates a significant difference 
between the animals treated with the same drug one and seven days after 
treatment concerning aflibercept but not ranibizumab. Also, only Aflibercept day 
1 differs significantly from the control and the difference between Aflibercept 
day 1 and Ranibizumab day 1 is on the edge of being significant. Of interest, 
means of Aflibercept day one are not only significantly different but also higher 
than means of other groups. (Annotation: In student´s t-test comparing each 
couple (not shown), the difference between means of Aflibercept day 1 and 
Ranibizumab day 1 is significant.) 
In the article published in PloS One [42], the untreated monkey was the only 
animal serving as control. This is based on the assumption that only one animal 
was truly “untreated” (the other animal which also served as control in the 
previous analysis was injected with a saline solution). Equally to the previously 
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described considerations, sample sizes should again be approximately equal. 
Thus, only about half the data obtained from each group of treated animals was 
taken into account for statistics. Therefore, values from three out of six 
glomeruli evaluated (from two monkeys in each group) were randomly chosen 
(see “A” and “B” in table 5). For statistics see [42]. The results are in 
accordance with those described in this work. 
table 5 shows the total number of pictures evaluated. It must be pointed out that 
the amount of pictures evaluated cannot be equalized with the amount of 
observations for the number of fenestrations per µm available. In one picture, 
several measurements are performed when there are multiple parts of 
glomerular endothelium seen. Thus, the total amount of observations (ratio of 
number of fenestrations per µm) is at 1382 (see table 3) correspondingly higher 
than the total amount of pictures evaluated. 
 “The total amount of pictures taken was 4855 of which 1327 (27.3%) were 
evaluated” [42]. On average, 486 pictures per procedure (A or B, respectively, 
with three glomeruli evaluated per procedure per time point) were available of 
which on average 132,7 were analyzed. Regarding a single glomerulus, on 
average 162 pictures were taken and 44,2 analyzed. Considering all the 
pictures evaluated for the treated animals (not the two controls), 809 pictures 
per modality (1002,3 when the two controls are not considered) were taken of 
which 221,2 (269,5 without controls) were evaluated (27,2 % /26,9%). Overall, 
the ratio of evaluated pictures/ pictures taken was about the same for each 
monkey/time point (24,7% to 33,8%). The amount of pictures evaluated was 
then also comparable with the control groups (Aflibercept Vehicle and 
Untreated) pooled (230 for Aflibercept day 1, 266 for Aflibercept day 7, 298 for 
Ranibizumab day 1, 284 for Ranibizumab day 7, 132+117=249 for controls).  
Table 5: Numbers of images taken and evaluated for the first and second 
statistical analysis 
Numbers and percentages of evaluated images with and without controls. Data shown per 
glomerulus, per procedure (A for article published, A + B for statistics of this work) and per time 
point (2 monkeys for treated animals, 1 monkey for controls) 
A: Glomeruli randomly chosen for the analysis published in [42], with 3 glomeruli per time point 
A+B: complete data used for the statistical analysis in this thesis, observations from 2 monkeys 
(6 glomeruli) per time point for treated animals  
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Software: Microsoft Excel for Mac 2011. 
 
 
5.3 Exclusion of errors of measurement 
To avoid gross errors, fixation and preparation of samples was documented and 
performed with the same detergents following a standardized protocol (see 
figure 18). Preparation and fixation procedures were performed by a single 
person from our work group (Tatjana Taubitz) within one week.   
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In my analyses, variability between measurements might occur mainly due to 
the fact that the line along the endothelium is manually drawn in the software 
program and due to the recognition or not of fenestrations by the observer. The 
number of images chosen for analysis did not vary on a big scale as criteria 
were very clear nor did the other named criteria as there was only one 
observer. Also, differences in picture quality with a possible influence on the 
recognition of fenestrations have to be taken into account. 
To minimize the random error of measurement, the mean value of repeated 
measurements can be calculated. The more measurements are performed the 
lower the error [177]. As the number of images taken was very high at 4855 and 
so accordingly the number of evaluated images (1327), the evaluation of three 
glomeruli per kidney/ time point can already be considered to be a repeated 
measurement reducing the random error. Moreover, in total up to 6 glomeruli 
per time point were evaluated for all the treated animals (and control animals 
when pooled).  
The statistical power can be assumed to be high due to the high number of 
observations. Moreover, the assumption of normality was inspected, with the 
result of all groups being approximately normally distributed. 
Test on equal variances 
Also, means were tested with the JMP 13 program for equality around the 
groups. Small p values as results of the test on equal variances suggest that 
the variances are indeed not equal in the groups. Hence, the Welch Anova F- 
test was applied in addition.  In this variance-weighted test F was 12,584 for 
analysis number 2 compared to an F value of 15,851 in the unweight Anova 
analysis. As the F value was highly significant in both cases and as being zero 
or larger than zero (not the exact value) is the only informative value of the test 
[176], inequality of variances was excluded as a major source of error.  
Moreover, as a prevention of falsely declaring significance, more attention was 
placed on the Tukey-Kramer- HSD test than on the t-test.  
6. Conclusion of Results 
The samples of the untreated animals as well as those of the animals treated 
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with aflibercept and ranibizumab one and seven days after injection were 
examined regarding three criteria: the histology (microscopically and ultra-
structurally), the immunohistochemistry and the ratio fenestrae/µm of the 
glomerular endothelial cells. Also, a measurement of VEGF-plasma levels was 
performed but all doses were below the detectable limit of the assay. 
In histological analyses, no abnormalities were seen in any of the samples in 
either light or transmission electron micrography.  
The anti-VEGF staining as well as the evaluation of reactivity against 
ranibizumab and aflibercept revealed that no reactivity against the injected 
drugs was detected in controls. However, differences in reactivity against the 
drugs were significant between controls and all treated animals in terms of 
higher values for treated animals. 
Concerning anti VEGF-stainings, mean values of the aflibercept-treated 
samples were significantly decreased compared to controls in contrast to 
ranibizumab-treated samples where no significant differences were observed. 
Also, mean values of samples treated with aflibercept were significantly lower 
one day as well as seven days after injection compared to ranibizumab-treated 
samples at the same time points. The decrease in the level of VEGF from day 
one to day seven was found to be significant for aflibercept-treated but not for 
ranibizumab-treated animals. 
The statistical analysis of the number of fenestrations of glomerular endothelial 
capillaries was complexly regarded. The distribution of values is always close to 
normality no matter which group is considered. Great effort was put into 
reducing errors of measurement and data was censored critically. Moreover, the 
sample size was very high considering the small number of monkeys in this pilot 
study. But as always advisable when data is statistically edited, the most 
cautious and assured conclusions are presented. The values obtained from the 
monkey treated with aflibercept and scarified one day after injection differ highly 
significantly from all values obtained from any other monkey (Anova, student´s t 
-test and Tukey-Kramer-HSD test) in the sense of having a higher number of 
fenestrations per µm than all the other groups. 
Also, significant differences were observed comparing the different time points 
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(days one and seven after injection) of the two animals injected with aflibercept, 
but not with ranibizumab when controls (the untreated monkey and the monkey 
injected with aflibercept´s vehicle) are pooled. Comparing the same time points 
and the two different drugs, significant differences comparing the means of the 
groups Aflibercept day 1 and Ranibizumab day 1 are evident. Seven days after 
injection, comparing the two monkeys injected with the two different drugs 
(Aflibercept day 7 and Ranibizumab day 7), the difference between mean 
values is not significant at the set alpha level of 0,05. 
 
In conclusion, it is evident that mean values of the group Aflibercept day 1 differ 
significantly from all other groups and control animals in the sense of higher 
group means. For other conditions, tendencies have to been kept in mind: The 
trend in the number of fenestrations seems to be higher especially one day after 
injection for the animal treated with aflibercept compared to the ranibizumab-
treated monkey. Also, the ratio of fenestrations per µm seems to decrease 
comparing days one and seven after injection of both drugs- an observation that 
is statistically significant for aflibercept-treated but not ranibizumab-treated 
samples.
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IV)  Discussion 
1. Analyses of eye tissue samples 
(All the following results were obtained and described by Sylvie Julien-
Schraermeyer and her co-authors in [148]). 
The results obtained from the ophthalmologic analyses of other members of our 
study group will be briefly summarized so as to compare the findings to those 
observed in the kidney. As already mentioned, the same monkeys and 
treatments were used. 
1.1. Ophthalmic examinations  
No abnormalities in any of the eyes or time points in funduscopy, FA and SD-
OCT were seen [148]. A significant increase in intraocular pressure directly after 
drug administration and a return to baseline ten minutes after drug 
administration was observed [148]. Regarding the measurements of intraocular 
pressure one day after injection of the two drugs, a significant decrease was 
seen. This decrease was only statistically significant for ranibizumab- treated 
but not for aflibercept-treated samples [148]. On day 7 after aflibercept injection, 
a significant IOP reduction compared to the untreated animal was seen. In 
contrast, the IOP of ranibizumab-treated animals normalized and reached 
baseline values 7 days after drug administration [148]. 
1.2. Immunohistochemistry of retina and choroid 
Distinct distribution patterns of immune reactivity were already observed one 
day after intravitreal injection of the drugs. These distributions evidently differ 
between ranibizumab and aflibercept: „Ranibizumab permeated the retina via 
intercellular clefts […], whereas aflibercept was taken up by ganglion cells, cells 
of the inner and outer retinal layers and the RPE […] Local accumulation in 
retinal and choroidal vessels was observed for both drugs […] Ranibizumab 
immune reactivity was reduced after 7 days compared with day 1 […] while 
aflibercept […] showed no changes. “[148]. Further immunohistochemical 
stainings indicated a mild activation of Mueller cells in the retina 1 and 7 days 
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after drug injections compared to controls [148]. Light microscopy revealed 
localized thrombocyte activation and fibrin formation in deeper choroidal 
vessels at day one and occasional stasis and hemolysis on day 7 after 
ranibizumab injection [148]. These findings were seen to a much greater extent 
in aflibercept treated samples where stasis and haemolysis occurred widely in 
the choriocapillaris samples examined [148]. Moreover, RPE was hypertrophic 
only in aflibercept treated samples and indications of RPE cell death were also 
found exclusively in these samples but on the other hand, photoreceptors did 
not seem to be affected  [148]. Quantification of the area occupied by the 
choriocapillaris and of free haemoglobin revealed that the choriocapillaris area 
was reduced one day as well as seven days after injection of both drugs 
compared to untreated controls [148]. Also, a significantly higher amount of 
haemolytic plasma was seen in the choriocapillaris one and seven days after 
aflibercept injection compared to corresponding ranibizumab samples (Wilcoxon 
test) was seen [148]. 
1.3. Quantification of choriocapillaris endothelial cell fenestrations and 
measurement of endothelial thickness 
The statistical analysis (Wilcoxon test) revealed a significant reduction in the 
number of fenestrae in the choriocapillaris after treatment with both aflibercept 
and ranibizumab compared to control samples [148]. Moreover, comparing the 
two drugs, the reduction in the number of fenestrations was significantly more 
predominant after aflibercept treatment at both time points[148].  The mean 
thickness of the endothelial wall decreased significantly when comparing 
treated animals and the control [148]. This effect was higher for aflibercept-
treated animals [148] and the effect seems to be higher by comparing 
specimens of aflibercept days 1 and 7 [148]. 
1.4. Discussion of retina and choriocapillaris analyses 
The possibility of an increase of the intraocular pressure after intravitreal anti-
VEGF injection can be discussed. The normal intraocular pressure in human 
eyes is between 10-21 mm Hg, fluctuating during the day [148]. In the 
performed experiments, circadian fluctuations can be excluded due to regular 
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performances of measurements. A short term reversible increase in IOP is a 
well-known phenomenon after intravitreal injections [178], mainly due to an 
increase of intraocular volume [148]. The amount of aqueous humor determines 
intraocular pressure. 
The ophthalmic examinations described show no detectable damage after a 
single intravitreal injection when funduscopy, FA and SD-OCT are performed, 
as it is clinical practice. We noted that there were no significant alterations of 
clinical observable parameters (of course, vision loss or gain could not be 
determined in a monkey experiment). 
Only with the more specific histological, immonohistochemical and ultra-
structural methods, early appearing effects of the drugs aflibercept and 
ranibizumab on the retina and choroid of these monkeys could be observed 
[148]. The study could provide evidence that the drugs permeate the retina in 
different ways: ranibizumab actively via intercellular clefts, aflibercept via uptake 
by ganglion cells, cells of the inner and outer retinal layers and the retinal 
pigment epithelium [148]. But further differences concerning the interaction of 
the drugs with the retinal tissues were seen. Particularly after aflibercept´s 
treatment more frequent stasis and haemolysis were seen with the 
consequence of hypertrophy and death of individual RPE cells [148]. Also, the 
thickness of the endothelium of the choriocapillaris and the number of its 
fenestrations was reduced and heamolytic areas were more prominently seen 
after treatment with aflibercept although similar effects were seen for 
ranibizumab treated samples [148]. 
It has to be discussed if these findings are related to the Fc domain or other 
aflibercept-specific characteristics [148]. Especially the observed protein 
complex formation induced by aflibercept [148] is similar to processes 
previously described for bevacizumab [86, 131, 134, 179-181]. It can be 
speculated that phenomenon occurring under aflibercept treatment can be 
attributed to the fact that –in contrast to ranibizumab- it also contains the Fc 
domain of human IgG1 [148]. Also, binding affinities differ between drugs used 
for intravitreal injections [148]. In detail, one molecule of bevacizumab binds two 
VEGF-dimers. For ranibizumab, the contrary is the case with two molecules 
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needed to bind one VEGF-dimer. One molecule of aflibercept binds one 
molecule of VEGF-A or placental growth factor, respectively [182], [148]. Two 
hypotheses of the interaction of aflibercept and bevacizumab with proteins are 
presented in [148], one of them assuming that a part of the VEGF is still 
accessible allowing protein complex formation in spite of aflibercept forming a 
VEGF trap [148]. 
Due to differences of drug production (in Chinese hamster ovary (CHO) cells) 
[148], aflibercept and bevacizumab contain sugar residues whereas 
ranibizumab is produced in bacteria (Escherichia coli) and lacks these residues 
[148]. An interaction of these sugar residues and aflibercept´s Fc domain might 
lead to red blood cell death through complement-activation [148], which is a 
possible explanation of the increased haemolysis found in the choriocapillaris in 
aflibercept-treated animals [148]. 
The role of VEGF in the maintenance of the choriocapillaris was previously 
described [183]. Consequently, a reduction of fenestrations as well as vessel 
occlusion is not surprising and has previously been investigated for 
bevacizumab [86] and also in the presently described study for the drugs 
aflibercept and ranibizumab, though with aflibercept having a stronger effect 
[148]. Also, free haemoglobin is proven to be toxic [184] and it can be 
hypothesized that it can have an effect on retinal pigment epithelium and 
endothelial cells [148].  
In summary, the most striking changes of these analyses were a reduction of 
the lumen of the choriocapillaris, haemolysis, microangiopathy, formation of 
protein complexes, RPE hypertrophy and cell death [148] with all of the 
changes mentioned, apart from the lumen reduction, being more distinct or 
even only present after aflibercept treatment [148]. Thus, the authors 
recommend observation of the interaction of aflibercept and especially its Fc 
fragment with other molecules and cells and further investigation of the clinical 
significances of these findings [148]. 
1.5. Analysis of ciliary body and iris 
(All the following results were obtained by Maximilian Ludinsky and analyzed, 
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described and discussed by me and Maximilian Ludinsky to the same degree in 
[150]; also see the declaration of personnel contribution on page 137 and 
appendix.) 
Apart from the retina and choriocapillaris, the ciliary body and iris of the 
monkeys were also examined. Of special interest here were the fenestrations of 
the blood vessels of the ciliary body, which have - similar to those of the 
choriocapillaris and the glomerulus - a VEGF-dependent fenestrated 
endothelium [150]. These vessels also nourish the iris [150] and as the aqueous 
humor produced by the epithelium of the ciliary body is mainly responsible for 
the maintenance of the intraocular pressure (IOP), the relationship of the 
number of fenestrations [89] and IOP to VEGF inhibition was also of interest. 
1.6. Immunohistochemistry/ light and fluorescence microscopy of ciliary 
body and iris 
Immunohistochemical methods (a goat antiserum to human Fab of IgG and a 
goat anti-human IgG-Fc antibody and for both a cy3-rabbit anti-goat antibody as 
a secondary antibody, followed by staining, embedding and inspection with a 
fluorescence microscope) were used to localize the drugs in the ciliary body 
[150]. Aflibercept was slightly stronger stained than ranibizumab but both drugs 
could be localized in the ciliary body with equal distributions and the stainings 
between days 1 and 7 did not differ [150]. Briefly, strong staining was seen in 
the blood vessels´ walls, some vessel lumen, the surface layer of the epithelium 
and the connective tissue of the vascular plexus. Other structures like the ciliary 
muscle and the cytoplasm of the endothelium were more weakly stained [150]. 
A slight difference was seen in the stroma of the epithelium in the aflibercept-
treated samples being more intensively stained in contrast to ranibizumab-
treated samples where the staining was more concentrated on the epithelial 
cells [150]. 
Also, VEGF was localized in ocular tissues. Therefore, the monoclonal mouse 
anti-human vascular endothelial growth factor was used as the first antibody, 
detected (REAL TM Detection System) and inspected by light microscopy [150]. 
The VEGF stainings were semi-quantified using high magnification light 
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microscopic images and the colour cube based^ function in the Image-Pro Plus 
software [150]. Here, the intensive staining of the pigmented epithelium of the 
ciliary body that could be seen in control samples was weaker in samples of 
treated animals (similar at the different time points) [150]. 
1.7.  Quantification of fenestrations in blood vessels of the ciliary body 
and histology 
In specimens prepared for electron microscopy, two different regions of interest 
per eye/time point and control containing parts of both the ciliary body and the 
iris were photographed and investigated. The number of fenestrations of all the 
blood vessels visible were counted and the ratio of the number of fenestrations 
per 10 µm was statistically evaluated. T-test against the control was performed 
(p<0,05 considered statistically significant) [150]. 
Morphological changes were seen in the posterior part of the pigmented 
epithelium of the iris of aflibercept-treated animals only [150]. The epithelial 
sections seen in samples of the animals treated with aflibercept and sacrificed 
on days one and seven contained multiple vacuoles in similar amounts [150]. 
Concerning the number of fenestrations, a statistically significant decrease was 
seen in samples of aflibercept on days 1 and 7 and ranibizumab on day 7 
compared to control samples [150]. 
1.8.  Discussion of ciliary body and iris analyses 
The ciliary body is- besides its lens-related functions- responsible for aqueous 
humor production and secretion [89] and its drainage [88]- the last named in 
combination with the trabecular meshwork and the canal of Schlemm [88]. 
A common disease related to intraocular pressure is glaucoma. If the drainage 
of aqueous humor is defective, the intraocular pressure rises. If this state 
persists, the optic nerve can be damaged, leading to progressive irreversible 
vision loss [185]. Besides this major high-pressure related form of glaucoma, 
states with decreased or normal intraocular pressure can also cause damage to 
the optic nerve. These cases are called low pressure or normal pressure 
glaucoma [185]. This subform is caused by abnormal ocular blood flow [186], 
whereas the risk dominating the whole group of glaucoma diseases is the 
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significant death of retinal ganglion cells [185, 186]   
As repeatedly discussed, neovascular eye diseases that go along with a 
pathologically increased formation of new vessels can strike the posterior part 
and cause wet AMD. But also the anterior part of the eye can be encompassed 
with the example of rubeosis iridis, a complication of diabetic retinopathy and 
central vein occlusion [150]. In this disease, neovascularization of the iris may 
lead to a special form of glaucoma, known as neovascular glaucoma [150]. 
“The underlying pathogenesis in most cases is posterior segment ischemia“ 
[187] followed by the formation of new blood vessels that obstruct aqueous 
humor outflow [187].  
The aim of glaucoma therapy is the lowering of intraocular pressure either by 
optimizing the drainage of aqueous humor or by reducing its production. 
Conventionally, topical beta blockers, prostaglandins (currently not so often) or 
alpha-2 antagonists and topical or oral carbonic anhydrase inhibitors are used 
[187]. The main therapeutic approach is photocoagulation [187], which in some 
cases needs to be accompanied by surgical procedures (trabeculectomy, 
glaucoma drainage devices, surgical carotid endarterectomy and others) [187]. 
Local anti-VEGF therapy is a comparably new therapeutic approach in the 
management of neovascular glaucoma diseases. Studies have shown that 
VEGF-A plays a role in the embryogenesis of the ciliary body as well as in the 
homeostasis and in the maintenance of the fenestrated phenotype of its 
capillaries in the adult [89]. In neovascular glaucoma patients, VEGF is mainly 
produced in the non-pigmented part of the epithelium of the ciliary body [187]. 
“Bevacizumab has already been used intracamerally and intravitreally for the 
adjuvant treatment of rubeosis iridis and neovascular glaucoma with promising 
results [119, 188-190]” [150].  Also, ranibizumab injections for the treatment of 
these diseases have been published [191-194]. More recently, aflibercept trials 
were also performed [195]. Lately, Rodrigues et al. [187] reviewed all the anti-
VEGF treatments performed in this field with the result that its long-term 
effectiveness in neovascular glaucoma remains to be further evaluated whereas 
there is evidence that an anti-VEGF pre-treatment before surgery might be 
helpful [187].  
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Similarly to the cited studies, our results also show that an effect of the drugs is 
detectable as the number of fenestrations was reduced in the ciliary bodies of 
all treated animals. This goes along with the fact that the drugs were also well 
detectable at their possible sites of action. Also, the VEGF-staining became 
weaker in treated animals, which can be interpreted as a VEGF-reduction due 
to the pharmacological effects of aflibercept and ranibizumab. To which extent 
this effect will help to not only stabilize the IOP but also increase vision and 
comfort for patients has to be further investigated. Also, the possible side 
effects of these intravitreal anti-neovascular treatments as well as effects over a 
longer period of time and after repeated injections need further studies. In the 
described study [150], no histological changes compared to the controls were 
seen. Also in previous studies with bevacizumab, this was not observed by 
other authors either [196]. 
Another point that has to be discussed is the reduction of fenestrations in the 
vessels of the ciliary body, the trend being even higher when the animals were 
treated with aflibercept [150]. In ranibizumab samples, a significant reduction 
was only detected seven days after injection. Apart from being a desirable 
effect in the treatment of neovascularization, this issue may have clinical 
impacts like defects of the pigmented epithelial layer [89], prolonged ocular 
hypotony and phthisis bulbi [197], [150]. 
The distribution patterns of the two drugs only slightly differed. In contrast to 
ranibizumab, which was highly concentrated on the cells of the ciliary body 
epithelium, aflibercept staining was more prominent in the stroma. It can be 
discussed if this is a sign of a better penetration of ranibizumab into epithelial 
cells, which again might be related to the differences in the molecular structures 
of the drugs. 
In particular, the vacuoles found in the posterior pigmented epithelium of the iris 
of aflibercept-treated animals need to be further discussed. They can hardly be 
related to physiological ageing processes [150]. In contrast to other 
morphological changes in ocular tissues [90, 93] vacuoles have not been 
described. Moreover, the human equivalent age of the study animals is 
between 13,8 and 16 years [150] making changes due to ageing in these 
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healthy animals improbable. Looking at pathological conditions, vacuoles filled 
with glycogen were found regularly in the eyes of diabetic patients [198] but 
also under malignant conditions (lung, prostate, leukemia) and are also known 
as microcysts of the iris pigmented epithelium [150, 199]. The observed 
vacuoles might for example be deposits or signs of oedema [150].  
Nevertheless, the content and significance of the vacuoles found in the iris after 
aflibercept treatment remains unclear. Especially uncertainty remains as it was 
shown that most evidence of a beneficial effect of pre-surgically administered 
anti-VEGF drugs in neovascular glaucoma was found for the reduction of 
hyphema [187]. This fact is contradictory to the assumption that the vacuoles 
found in the iris are signs of oedema.  
In summary, intraocular pressure has to been kept within strict limits although 
the tolerance might also be individual- dependent. The use of anti-VEGF agents 
in the treatment of patients with neovascular glaucoma is relatively new and its 
effectiveness and possible side-effects need to be further investigated. It must 
be seen whether it can offer a useful addition to proven and tested treatment 
regimens like photocoagulation and surgery. Future trials will show which of the 
available drugs is also more effective concerning clinical vision improvement 
with the least possible side-effects. Patients being treated against wet-AMD or 
rubeosis iridis/neovascular glaucoma might benefit from the higher affectivity of 
aflibercept in neutralizing VEGF which was found in this monkey study. 
However, aspects of this study indicate that further research is advisable to rule 
out any unexpected side effects [150]. 
1.9.  Conclusion of analyses of eye tissue samples 
The VEGF concentration was reduced in the ciliary body pigmented epithelium 
after treatment with both drugs [150]. This and the significant reduction of 
fenestrated endothelium in the choriocapillaris [148] as well as in the ciliary 
body [150] is an indication of the local impact of the drugs [148]. The slightly 
different distribution patterns of the drugs were not very distinct in the ciliary 
body where aflibercept´s concentration was higher in the stroma in contrast to 
ranibizumab which was more concentrated on the cells of the ciliary body 
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epithelium [150]. In other ocular tissues the differences in distribution are more 
evident. More precisely, concerning the penetration of the retina different 
physiological processes have been revealed for aflibercept and ranibizumab 
[148]. As an explanation, the different molecular structures of the drugs may 
account for this [148].  
The drugs could be detected in ocular tissues. Namely these were the ciliary 
body [150], the retina and the choriocapillaris [148]. Also, an effect of the anti-
VEGF drugs in the sense of a reduction of fenestrations in VEGF-dependent 
tissues like the endothelium of the capillaries in the ciliary body [150] and the 
choriocapillaris [148] was observed. The number of fenestrations was reduced, 
with an effect tending to be higher in aflibercept-treated samples [148, 150]. No 
clinically observable changes in the eyes of the untreated as well as the treated 
monkeys, apart from a temporary increase in IOP (as described above) were 
seen. This increase can be explained and thus the additionally found 
morphological changes revealed by immunohistochemical and ultrastructural 
analyses have to be further investigated. Especially the significance of the 
vacuoles found in the posterior pigmented epithelium of the iris of aflibercept-
treated animals currently remains speculative. 
2.  Analyses of kidney samples 
2.1.  Immunohistochemistry/ fluorescence staining of kidney samples 
(analyzed and described by Alexander Tschulakow in [42].) 
To evaluate the distribution of VEGF, aflibercept and ranibizumab in the kidney 
glomeruli of the monkeys, three staining methods were performed. After 
determining the area of interest, normalization and estimating the ratio of 
stained area/ cell count, samples from the untreated control animal were 
compared to treated animals and values of treated animals were statistically 
compared as well [42].  
Staining of samples was carried out with a primary mouse antibody against the 
human IgG-Fab- fragment and a primary mouse antibody against the human 
IgG- Fc-fragment to test immune reactivity against ranibizumab and aflibercept, 
respectively. In addition, a fluorescent staining with corresponding antibodies 
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for the two drugs was performed [42]. These procedures revealed that the 
drugs were indeed detectable in the corresponding samples one and seven 
days after injection whereas there was no immune reactivity against the drugs 
in control samples [42]. 
Anti-VEGF staining was performed using primary mouse anti-VEGF antibodies. 
The analyses of the stained samples showed a significant decrease of VEGF 
levels in aflibercept-treated but not in ranibizumab-treated animals. Comparing 
samples from the two drugs at the same time points, VEGF levels were 
significantly lower in aflibercept-treated samples one and seven days after 
treatment. Also, the decrease in the VEGF level was only significant for animals 
treated with aflibercept [42]. 
2.2.  Discussion of Immunohistochemistry/ fluorescence staining of 
kidney samples  
It is not surprising that intravitreally injected anti-VEGF agents reach systemic 
circulation. But neither was it examined whether these agents also are 
detectable in distant organs like the kidneys nor if they have a measurable 
effect on the fenestrations of glomerular capillary endothelia.  
Drug clearance from the vitreous might depend on molecular size as small 
molecules have a terminal half-life (t1⁄2) of several hours when intravitreally 
injected whereas larger molecules have a terminal t1⁄2 of several days (albumin 
4,3 days with a molecular size of 67kDa, the full-length antibody trastuzumab 
5,6 days with 148kDa) (reviewed by [200]). Also, the size of the eye might 
contribute, as clearance is quicker in rabbits than in monkeys and might even 
be slower in humans [200]. Thus, it can be expected that the antibody fragment 
ranibizumab with its molecule size of 48 kDa might be cleared more quickly 
from the eye than aflibercept with 115 kDa. 
For ranibizumab, it was shown that once intravitreally injected, it is cleared from 
the eye into the circulation with a half-life of approximately 3 days in 
cynomolgus monkeys and with fifty percent of the dose reaching the circulation 
after 2 days [200]. Nevertheless, serum concentrations can be expected to be 
very low as a relatively small dose is administered and distributes over the 
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whole blood volume of the individual where it is probably cleared quickly [200]. 
Moreover, in our studies the drugs were only administered once whereas 
repeated monthly or on-demand doses are needed and performed clinically 
[201]. 
Studies showed that ranibizumab can be found in the serum but the 
concentrations detected were considered below the necessary threshold for a 
sufficient VEGF inhibition [202]. As the serum clearance half-life of ranibizumab 
is 3 days, our detection of the drug in the kidneys of the treated animals in 
keeping with these pharmacokinetics. It is possible that the drug already 
reached systemic circulation one day after intravitreal injection, and referring to 
this relatively long serum half-life, it is possible that there is also still some inflow 
into the kidney seven days after injection, offsetting the physiologically 
appearing elimination. Moreover, since ranibizumab is not protected from serum 
elimination by an Fc-fragment, it has been suggested that it is rapidly cleared 
from the circulation via renal elimination [42]. Thus, it can possibly accumulate 
in the kidney for a certain time whereas its dose in systemic circulation is very 
low and its systemic anti-VEGF activity is not detectable. This is in keeping with 
the findings in this study. Both drugs were detected within the glomeruli but 
VEGF levels in the glomeruli were not significantly affected by ranibizumab. 
Moreover, one day after ranibizumab injection, the endothelium cell layer and 
erythrocytes of most glomeruli showed specific fluorescence against human Fab 
of IgG which was nearly lost seven days after injection of ranibizumab [42]. This 
process might be almost ended 7 days after injection, which conforms to the 
determined half-life of ranibizumab of approximately 3 days.  
For aflibercept, similar considerations have to be assessed. In order to 
understand its pharmacological characteristics, it has to been kept in mind that 
aflibercept is designed as a cytokine trap consisting of two extracellular cytokine 
receptor domains fused together to form a human immunoglobulin G (IgG) 
[203]. It has been published that aflibercept, in contrast to bevacizumab, binds 
VEGF-A in a 1∶1 stoichiometry [204]. These aflibercept-VEGF complexes 
remain stable in the systemic circulation [204]. The authors speculated that 
because of this stoichiometry and the inert nature of the complexes, aflibercept 
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is not expected to accumulate in renal glomeruli [204] as has been found for 
bevacizumab. In a rabbit model the vitreous elimination half-life was 
approximately 4.5-4.7 days (reviewed by [205, 206]). Nevertheless, it has to be 
kept in mind that rodents have smaller eyes than primates and the eyes of 
humans are even bigger, and also that the half-life of aflibercept in the human 
eye has not been determined [206]. Thus, the half life can be expected to be 
even longer, assuming a long-term VEGF- blockade by aflibercept, which could 
be attributed to the stronger and prolonged binding of aflibercept to the VEGF-A 
receptor [205]. Also, experimental studies indicate that aflibercept penetrates all 
layers of the retina after intravitreal injection (molecular weight∼110,000) with 
the least possible systemic exposure [207]. 
Considering the mentioned pharmacokinetics that can be expected for 
aflibercept and especially due to its measured vitreous elimination half-life of 
approximately 4.7 days in rabbits and its molecular size being more than double 
that of ranibizumab, our findings are surprising. Already one day after 
intravitreal aflibercept injection, the endothelium cell layer and material within 
the capillaries of many glomeruli were highly fluorescent after labeling with an 
antibody against the Fc region of IgG [42]. We wouldn´t have expected a 
measurable amount of the drug to be able to escape from the eye and 
accumulate in the glomeruli so quickly. The decrease in intensity of this 
fluorescence on day seven after aflibercept injection is despite the expected 
long-term survival and stability of aflibercept-VEGF complexes. It is less 
surprising as any decrease would be physiological and because the amount of 
the decrease was not quantified in this study. On the other hand, a theoretically 
possible cross-reactivity of the injected antibody (a primary mouse antibody 
against the human IgG-Fc-fragment) with the Fc receptors or other Fc-domains 
containing proteins of the monkey has to be taken into account. 
In anti-VEGF staining, a significant decrease in the mean VEGF level/cell ratio 
was only seen for aflibercept, but not for ranibizumab samples [42]. This was 
the case for both time points compared to untreated control-animal samples 
and to ranibizumab samples. A rationale for this was presented by Al-Halafi 
[205] who reviewed results of other authors [203, 208] indicating that aflibercept 
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should have more extended binding activity than anti-VEGF monoclonal 
antibodies like ranibizumab and bevacizumab. Aflibercept theoretically binds 
VEGF more tightly than native receptors or monoclonal antibodies [205]. These 
considerations might explain our findings of an apparently more effective 
VEGF-inhibition by aflibercept. 
In 2012, when the present studies were performed, aflibercept was a new anti-
VEGF drug. For safety considerations, two similarly designed, double blind, 
multi-centre, active-controlled, randomized controlled trials (VIEW 1 and VIEW 
2) were about to be performed. They resulted in aflibercept being non-inferior to 
ranibizumab in efficacy in maintaining vision in treatment-naive patients with 
wet AMD after one year [209]. The safety profile of the two drugs was 
considered to be similar and it was assumed that with aflibercept, less frequent 
injections could be necessary [209]. On the other hand, due to different 
molecular designs and binding affinities, differences would not be surprising. As 
already mentioned above, differences in the molecular interaction of the two 
drugs were also found in examinations of the retina of the same monkeys [148]. 
They found differences in the molecular interaction of the two drugs with the 
retinal tissues concerning the penetration of the retina, hemolysis and protein 
complex formation (see above): “Ranibizumab permeated the retina through 
intercellular spaces, whereas aflibercept was taken up by neuronal and retinal 
pigment epithelium (RPE) cells“ [148]. Aflibercept induced protein complex 
formation and more hemolysis in the choriocapillaris, leading to individual RPE 
cell death. The clinical significance and relation of these findings to the Fc 
domain or to other characteristics of aflibercept remain to be investigated. 
Also, differences in the effectiveness of VEGF elimination and reduction of 
fenestrations were seen between the two drugs in the sense of a higher effect 
with aflibercept [148, 150]. Moreover, the formation of vacuoles in the iris after 
aflibercept- treatment in these monkeys currently remains unexplained [150]. As 
already mentioned above, the origins of the observed differences of the drug´s 
effects as well as possible clinical impacts need to be further investigated. 
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2.3.  VEGF-A plasma levels 
As we expected the two intravitreally injected drugs to escape the eye and 
reach systemic circulation, the aim of this analysis was to determine whether 
VEGF-A plasma levels were affected compared to control samples. For this 
purpose, EDTA blood samples of all monkeys were collected before intravitreal 
injection (predose) and on days one and seven after injection of anti-VEGF 
agents. Plasma was prepared by centrifugation and the blood samples were 
analyzed using commercially available ELISA kits for human VEGF-A (DVE00) 
(R&D Systems, Minneapolis, Minnesota) [42]. This kit uses human VEGF-A 
specific antibodies and an enzyme-linked polyclonal antibody specific for 
human VEGF-A and a substrate solution employing the quantitative sandwich 
enzyme immunoassay technique. Color develops in proportion to the amount of 
VEGF bound in the initial step. The color development is stopped and the 
intensity of the color (Optical Density) is measured by photospectrometry and 
VEGF concentration is calculated. The lower detection limit of VEGF-A of this 
array is 30 pg/ml (for more details see [42, 155]). 
We were unable to measure plasma VEGF levels since the concentrations were 
always below the detectable limit of the assay [42].  
2.4. Discussion of VEGF-A plasma levels 
“Larsson et al., have determined in 80 serum and EDTA plasma samples of 
healthy humans that the mean value ± SD of VEGF in plasma was 32 ± 21 
pg/ml [210]” [42].   They used the same array we did and no influence of age or 
sex was seen. Thus, we cannot exclude nor imply an effect of aflibercept or 
ranibizumab on VEGF serum levels as the actual concentration or any change 
in it was not measurable in our samples.  
On one hand, “the use of serum instead of plasma would be (conceptually) 
preferable since serum VEGF levels are several fold higher than plasma levels, 
because platelets express VEGF and secrete it during blood clotting [211]” [42].  
Webb et al. reported that serum VEGF levels were higher than plasma levels in 
adults (249.4 +/- 46.4 versus 76.1 +/- 10.7 pg/ml, P < 0.0001)[211]. On the 
other hand, though measuring of the levels would have been easier with serum, 
IV) Discussion 
 
 
76 
plasma seems to be the preferred medium to measure true VEGF levels as 
VEGF secretion by platelets during clotting is significant and highly variable 
[211]. 
Following mathematical calculations, “the systemic half-life of aflibercept is 
approximately 1.5 days and is greater than that of ranibizumab (6 hours) and 
less than that of bevacizumab (20 days)” [206]. Maximum systemic 
concentrations of aflibercept are achieved approximately 2–3 days after 
intravitreal injection, and these maximal concentrations are estimated to be 
approximately 200-fold less than the concentration required for maximal VEGF 
binding [206, 212]. Therefore, it is unlikely that aflibercept will reduce systemic 
VEGF concentrations to a level that will disrupt key homeostatic mechanisms 
required for normal cardiovascular function [206]. Heier et al. did not detect 
aflibercept in the systemic circulation 2 weeks after intravitreal administration 
[115]. 
Data from oncology trials have shown that systemic clearance of aflibercept 
occurs by two major pathways [213]. The first pathway involves renal clearance 
following binding of VEGF, and this occurs when serum concentrations of 
aflibercept are relatively low. The second pathway occurs during states of 
relatively greater aflibercept concentration and involves pinocytic-mediated 
mechanisms and elimination by proteolysis [206]. After a single intravitreal 
injection, serum aflibercept concentrations can surely be assumed to have been 
very low in these studies. Thus, the renal pathway of elimination is most 
probable. This might partly explain why aflibercept was detected in the kidneys 
of all monkeys. 
Preclinical pharmakocinetic analyses of ranibizumab after a single intravitreal 
injection performed by Gaudreault et al. [200] revealed that ranibizumab´s 
clearance from all ocular compartments had a terminal half-life or approximately 
3 days after a single bilateral intravitreal injection with 500 or 2000 µg per eye. 
They also detected ranibizumab in the serum with concentrations they 
considered to be below the necessary threshold for a sufficient VEGF inhibition 
[202], [42]. Thus, comparably to the present study, in the study performed by 
Gaudreault et al. [200] both eyes were injected and the total dose reaching 
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systemic circulation might be about doubled. Also, the pharmacokinetics 
regarding a single eye as well as the chronological sequence of the maximum 
serum concentration is comparable. One group of the monkeys in Gaudreault´s 
experiments was injected with the same amount of ranibizumab as in the 
present animal study (0,5mg = 500µg as also clinically practiced in humans). 
Even when more material (2000µg = 2mg) was intravitreally injected, serum 
concentration remained very low (150 and 616 ng/ml for 500 or 2000µg 
injected, respectively) and reached its maximum values after 6 hours [200]. In 
ocular compartments as in the serum, t ½ was approximately 3.5 days [200]. As 
a rule to compare the obtained results to the conditions in my study, “the overall 
ranibizumab concentration after ITV administration was >1500-fold lower than 
the corresponding vitreous concentration“ [200]. Thus, in contrast to the 
mathematical calculated systemic half-life of six hours [206], the obtained half-
life in the animal experiment was here 3.5 days for ranibizumab. 
Avery et al. [141] stated that a lowering of systemic VEGF levels after 
intravitreal injection is much higher in the treatment with bevacizumab than with 
ranibizumab [141]. In comparison with aflibercept-injections, the systemic 
exposure after the third monthly intravitreal injection should be 13-fold greater 
for aflibercept than ranibizumab and 70-fold greater for bevacizumab than 
ranibizumab [141]. In summary, the systemic effect of ranibizumab appears to 
be the lowest, consistent with pharmacological differences between the agents 
[141], as already mentioned in the introduction part of this work. As systemic 
VEGF levels were not measurable, these assumptions could neither be proved 
nor refuted.  
2.5.  Quantification of the glomerular endothelial fenestrations and 
glomerular histology 
The aim of quantifying the glomerular endothelial fenestrations and evaluating 
glomerular histology was to examine possible effects of the two intravitreally 
injected anti-VEGF agents on this strongly VEGF-dependent cellular 
phenotype. 
For details concerning Material and Methods as well as Results, please see the 
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corresponding sections of this work. 
No pathologic morphological changes were seen.  
2.6. Discussion of the quantification of glomerular endothelial 
fenestrations 
Statistical analyses 
In the present study, examples of factors with an influence on the dispersion 
around the average value in a Gaussian distribution can be named: the 
observer, the picture quality/ the adjustment of the electron microscope, the 
fixation and preparation method, the individual monkey, the injected drug, the 
injection procedure, the concentration of the drug in the individual glomerulus, 
the randomly chosen excerpts of the glomeruli, the counting method and choice 
of images for evaluation. These factors and their possible influence on obtained 
results have to be discussed. 
One would expect the control animal to have a more fenestrated glomerular 
endothelium as the anti-VEGF drugs used in the eye lead to a reduction of the 
number of VEGF-induced fenestrations in the retina. This was observed for 
bevacizumab in monkeys by Peters et al [86] and also in rats after 
bevacizumab-treatment by Shimomura et al [214]. After multiple injections of 
bevacizumab, Sugimoto et al saw a noticeable reduction in rabbit eyes [196]. 
Julien et al [148] also described a reduction of the number of fenestrations after 
the injection of ranibizumab but more prominent after aflibercept injection in the 
same monkeys as in this study. But in the statistical analyses for the kidneys 
performed –at least initially- this expected effect was not seen in the kidney but 
rather its contrary of an increase in fenestrations one day after intravitreal 
injection of the drugs. The not statistical significant trend of a reduction of the 
number of fenestrations can be seen in the course of time for the ranibizumab-
treated animals comparing days one and seven after injection (samples of the 
untreated animal and the animal injected with aflibercept´s vehicle pooled as 
control or only the untreated animal serving as control). For aflibercept, the 
increase in the number of fenestrations is statistically significant comparing 
days 1 and 7 and besides this, a statistically significant increase in the number 
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of fenestrations per µm compared to the control group/-s and all the other 
groups was observed. 
Error of measurement 
Evaluating the statistical analyses, errors of measurement also have to be 
considered. A gross error or random error would have occurred for example if 
the fixation method or detergents had been changed for this single experiment 
or samples. Due to good documentation of the fixation procedure, which was 
performed for all samples in the same way and within a short period of time by 
the same person, this can be excluded. Also, the adjustment of the electron 
microscope causing images which are hard to interpret or sharper compared 
images taken by other groups could modify the statistical analyses significantly. 
Indeed, images taken of samples of aflibercept day 1 are extremely sharp, but 
they absolutely do not differ from other samples in a way that would allow 
interpreting more or less fenestrae as comparable images show. This would in 
part explain the significantly higher amount in the number of fenestrae in the 
group Aflibercept day 1. On the other hand, the variation between Aflibercept 
day 1 and the other samples does not seem to be high enough to consider a 
gross error possible. 
Another possibility is that a random error occurred due to the natural variability 
of biological objects- in this case the specific monkey or the interaction of this 
monkey´s physiology with the drug. To be sure, the experiment would have to 
be repeated with another monkey or with a higher number of individuals per 
time point, which extends the possibilities of this study.  
Another possibility of minimizing the random error of measurements would have 
been to carry out repeated measurements of different glomeruli, thus producing 
a high number of different images, or alternatively performing repeated 
measurements of the same images. Moreover, more than one blinded observer 
could have performed the analysis assuming either a different adjutancy of the 
electron microscope or differences in the counting results of fenestrae/ µm. Due 
to the already very high sample size, cost and effort, these procedures were not 
performed. 
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Here again, biological variability and the possible non-distinguishable 
interaction of the organism of the control animal with aflibercept´s vehicle (a 
saline solution) have to be mentioned. This condition appears negligible due to 
the fact that there were no abnormalities detected in either the in-depth 
examinations of the eye tissues [148] or in my analyses of the kidneys of this 
control animal.  It is known that the untreated monkey showed aplasia of the left 
kidney. This might have influenced the perfusion of the remaining organ and 
thus the concentration of the drug in the kidney. This modality would not have 
been integrated in statistical analysis. Uncertainty may remain as excessive 
blood and urine analyses aren´t existent. 
It should be noted that “the heterogeneity of experimental animals regularly 
causes a considerable random sampling error as the dependent variable is 
often more influenced by deranging factors than by the examined factor” [177] 
and is not only implied in this pilot study although the influence of one individual 
animal is comparably high due to the small number of animals. But again on the 
other hand, I could show that group means of the two control animals did not 
differ significantly which makes natural variability as a source of error 
improbable. 
Another point worth being discussed is the theoretical possibility of taking 
kidney biopsies from each animal prior to treatments. These baseline values 
could be used to reduce the uncertainties about the influence of the individual´s 
physiology on the experiments. However, the benefit of these procedures 
compared to the effort necessary as well as the additional deranging factors 
possibly caused (additional stress on animals, amount of sample material 
necessary for qualified analyses etc.) remains speculative.  
In conclusion, the slightly better picture quality of the samples of aflibercept day 
1 as well as the possible natural variability (especially concerning the monkeys 
injected with aflibercept and sacrificed one day after injection and the monkey 
injected with aflibercept´s vehicle/ the two control animals) has to be 
considered, but also an actual effect of the drug aflibercept one day after 
injection is possible. Which effect aflibercept may cause in the kidney that might 
increase glomerular endothelial fenestrations is left to speculation. The 
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statistical significant reduction of fenestrations also observed in the course of 
time in aflibercept as well as a trend of reduction in ranibizumab samples also 
requires to be further studied. 
Moreover, the general aspects of statistical analysis have to be considered. 
When no statistically significant difference could be detected, it does not mean 
that the means of the other samples are the same.  In terms of statistics, you 
can only say that “there wasn´t enough evidence to show that they are different” 
[176]. A significant difference could have possibly been shown by collecting 
more data. 
Pooling of control samples 
As sensitivity and power analysis comparing these two samples revealed, 
around 70 percent more observations would have been necessary to detect a 
significant difference at an alpha level of 0,05. Actually, more observations than 
the LSN (least significance number) are advisable [176] as the “probability of 
finding a significant difference with LSN observations can be as low as 50%)” 
[176]. In conclusion, one can say that these two samples are congruent to a 
great extent. 
Power 
To increase the power of the statistical analysis, a couple of strategies can 
theoretically be considered. They include administering a large difference in 
doses [176], which would not have been reasonable as clinically the same 
doses are always applied and as this study was supposed to mimic clinical 
conditions in humans. A completely balanced instead of an unbalanced design 
[176] could have been realized with the same amount of measurements per 
group/ animal. On the other hand, this would not be in agreement with the study 
design to scan a whole glomerulus following the random SURS protocol as 
glomeruli do have different diameters. Also, the data can be considered to be 
roughly balanced due to high congruencies of sample sizes. The possibilities of 
increasing homogeneity of the subjects and thus reduce “noise” [176] was 
extended as far as practically realizable. The sample size was large with its total 
of observations compared to the number of variations (6 or 5 different groups 
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depending on the definition of the control group) due to the SURS protocol.  
Anyway, these points might be important to consider, but do not have any 
practical appliance here as the power is already maximized with the value of 1 
and does not change even if the alpha level is decreased remarkably (to 
>0,00001). 
Discussion of results of the quantification of glomerular endothelial cell 
fenestrations 
The use of monkeys was absolutely necessary in this study as it also aimed to 
compare the effects of different drugs with different molecular structures. We 
carried out our research to examine possible side effects also probably caused 
by the existence or not of an Fc domain of the injected drugs. In contrast to 
rodents, the interaction between the Fc domain and the Fc receptors in 
monkeys mimic those present in humans [215]. In contrast to the fully human 
recombinant fusion protein aflibercept that contains the Fc region of human 
IgG1, ranibizumab is an Fc-domain- free antibody fragment. Members of our 
group had previously examined the effects of intravitreal bevacizumab on ocular 
tissues [86, 131, 134, 179] with local side-effects being among others reduction 
of the choriocapillaris lumina, number of fenestrations, photoreceptors´ 
damage, formation of immune complexes and thrombotic microangiopathy. 
Different rationales especially for the thrombotic microangiopathy were offered. 
In brief, interactions of bevacizumab with thrombocytes [181] and activation of 
the complement cascade [180] were discussed and were mainly traced back to 
the Fc domain and complex formation with VEGF or heparin. It can thus be 
discussed if this set of problems might be reduced with the use of ranibizumab. 
Therefore, our group aimed to expand these studies to other drugs. In a 
previous study on the local effects of intravitreally injected ranibizumab and 
aflibercept performed in the same group of monkeys used in the present study, 
different interactions of the two drugs with ocular tissues were observed [148]. 
Julien et al. showed that besides different mechanisms of retina penetration, a 
reduction in the area of choriocapillaris was seen with both drugs. In aflibercept-
treated samples, the reduction of the choriocapillaris endothelium thickness, 
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number of fenestrations and the areas with haemolysis were more pronounced 
than in controls or ranibizumab- treated samples. Whether this is linked to the 
Fc fragment of aflibercept remains suggestive. 
We detected both drugs after both time points (one and seven days after 
injection) in the kidneys. The question was whether any effect on glomerular 
endothelial cell fenestrations could be measured. No significant reduction of the 
number of fenestrations per µm was found. In contrast and also surprisingly, 
aflibercept seemed to increase the number of fenestrations one day after 
injection compared to the controls or ranibizumab-treated monkeys. 
Simultaneously to VEGF-levels, the numbers of glomerular endothelial 
fenestrations per µm were not affected by ranibizumab to the same extent as by 
aflibercept. 
The fact that VEGF expression in glomeruli has to be strictly regulated and the 
consequences of its dysregulation have already been described in the 
introduction section of this thesis. Other authors have already described a wide 
range of renal diseases occurring within weeks or months after intravitreal 
administration of VEGF inhibitors [216, 217], [42]. Also, there has been 
evidence that intravitreally injected drugs are absorbed systemically from the 
eye and can inhibit VEGF [216, 218-220], [42]. 
The differences in their molecular structures have also been suspected to 
influence on the elimination of the drugs. Not containing an Fc-fragment, 
ranibizumab is not protected from being eliminated from the serum. Thus, it 
might be rapidly cleared from circulation via renal elimination with a resulting 
serum concentration that is not sufficient for VEGF inhibition [200, 202] [42]. 
These assumptions seem to be in accordance with our data [42] as we could 
localize ranibizumab in the glomeruli of our samples one and seven days after 
intravitreal administration of the drugs but neither the VEGF levels nor the 
number of fenestrations was significantly influenced [42]. 
In contrast to ranibizumab, aflibercept does contain an Fc-fragment. Its binding  
stoichiometry to VEGF-A has been reported to be 1:1 [204]. Moreover, this 
complex remains stable in the circulation [204]. These two facts motivated the 
authors to speculate that the aflibercept-VEGF-A complex is inert and thus 
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aflibercept does not accumulate in renal glomeruli as does bevacizumab [204], 
[42]. The present study confirms these assumptions as for the first time 
aflibercept was detected in glomeruli after intravitreal injection [42]. Just as 
interesting: we detected a significant reduction of the glomerular VEGF level 
after aflibercept-treatment [42]. 
However, this study also reveals a rather unexpected result: As a consequence 
of the reduced VEGF level, not a reduction but an increase in the number of 
fenestrations was observed [42].  Peters et al.  described a reduction of the 
number of fenestrations in the choriocapillaris after intravitreal anti-angiogenetic 
therapy [86]- a phenomenon which would have appeared plausible for the 
kidneys in this study as well [42]. 
It is not yet completely clear to which extent regulation of fenestrations differs in 
the kidney and choriocapillaris. Ultrastructural analysis revealed and it is 
commonly accepted that the fenestrated endothelium of the choriocapillaris is 
covered by diaphragms [86].  In the kidney, the regulation of glomerular 
endothelial cell fenestrations seems to be very complex [42]. As an example, 
the development of endothelial fenestrations in the kidney is dependent on 
TGF-β1 which it is not in the choriocapillaris [221], [42].  
Another point that is controversy discussed is the existence or not of fenestral 
diaphragms in glomerular capillaries [46], [42]. A protein that is closely 
connected to this consideration is PV-1 (plasmalemmal vesicle-associated 
protein-1) [46], [42].  This protein is part of fenestral diaphragms and some 
authors suspect it to play a role in the formation of endothelial cell fenestrations 
[46]. If this protein is not found in endothelia, this fact is supposed to be 
equalized with a phenotype of fenestrations without diaphragms or with a 
matured endothelium as PV-1 is supposed to be necessary for the maturation 
of fenestrations and disappears in the course of time [46, 222] . Also, these two 
groups of scientists assume that this protein can be re-expressed in the case of 
damage and repair of endothelial cells and that diaphragms might re-appear 
under these circumstances [46, 222], [42].  
We can thus speculate that the two proteins VEGF and PV-1 are expressed in 
the developing glomerular endothelium whereas only VEGF is vital to maintain 
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the fenestrated phenotype and PV-1 can be re-expressed in case of damage 
[46], [42]. Along with this speculation goes the variable presence of diaphragms 
[46], [42] as well as the observation of a “reduction of fewer fenestrations by 
local or systemic VEGF- inhibition [68]” [42].  
However, there are groups of scientists who have made contradictory 
observations in the sense of a constant coverage of the glomerular endothelium 
with a diaphragm [47-49], [42]. Additionally to this discussion of a stable or 
variable existence of diaphragms, fixation procedures and their effect on the 
recognition of these structures have to be considered [42]. “In our study, the 
fenestrations of the glomerular endothelial cells of adult monkeys were clearly 
not closed by diaphragms (Fig. 3A in [42]) which contrast to those observed in 
the choriocapillaris and reported in one of our previous monkey studies (Fig. 6 
in [86])” [42]. It should be noted that in this case we can exclude an influence of 
the techniques used but have to consider the fact that- in contrast to clinical 
practice- only a single administration of the anti-VEGF drugs was performed 
[42]. Moreover, in contrast to many patients requiring intravitreal anti-VEGF 
treatment, the monkeys in this study did not have a history of metabolic disease 
like diabetes which often manifests as diabetic retinopathy [42]. This 
microvascular disease might also affect the kidney and an intact VEGF-A 
secretion from podocytes has to be ensured for proper cellular functions [74], 
[42]. There has been a single report about a non-diabetic patient whose kidney 
functions had been unremarkable before the antiangiogenetic treatment of their 
wet AMD but who developed kidney toxicity after four intravitreal injections of 
bevacizumab [216], [42]. This might have been a rare event, but it advises 
caution. In diabetic patients, renal side effects are well-known after these 
procedures [218, 220, 223], [42]. 
 “Unfortunately we have no data concerning the urinary sediments. It would be 
of great interest to analyze them, especially as there are indications that anti 
VEGF therapies have influence on the kidneys, and can cause proteinuria and 
hypertension [224-226]. The analysis of the urinary sediments will also be an 
aim of our further studies.” [42]. 
No morphological changes were seen in any of the kidney samples which 
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differs clearly from the results obtained from the retina of these monkeys. For 
example in contrast to the choriocapillaris, no microangiopathy or hemolysis 
was seen in any of the samples. If  this is due to a lower drug concentration and 
if these observations would differ after repeated treatments or a longer timer 
period, cannot be concluded. 
 
Is the increase of fenestrations one day after aflibercept injection a sign of a 
reaction of the glomerular endothelium to sheer stress or the potential damage? 
And why did the number of fenestrations tend to decrease again on day 7 after 
injection? Why was this phenomenon not seen to a comparable extent in 
ranibizumab treated examples? To answer these questions, PV-1 expression 
measurements are required. Moreover, in our studies, the tendencies can be 
seen of higher numbers of fenestrations on day 1 compared to day 7 in both 
aflibercept and ranibizumab samples (thus not statistically significant in 
ranibizumab groups). Due to the small number of study objects in this pilot 
study, it remains unclear if this is of clinical importance and if the possible 
decrease in number of fenestrations is due to the effect of VEGF- inhibition or 
due to a reaction of the endothelium on a possible impairment. The next 
question would be if this is a reaction to the specific injected drug or the VEGF 
inhibitory effect of the drug. “What might happen if VEGFA is affected in a 
stimulated system is speculative and should be investigated. This might be a 
consequence of different antibody design. The immune complexes might be 
(an) inductor of thrombotic microangiopathy in the kidney [227]. Caution is 
needed when patients […] (who) might also already […] (have) renal disease 
are locally treated with these substances as they might definitively have 
systemic effects.” [42]. 
2.7. Conclusion of analyses of kidney tissue samples 
Already one day after a single intravitreal injection, both drugs could be 
detected within glomerular capillaries using immunohistochemical methods. A 
significant reduction of the anti-VEGF immune reactivity one day after injection 
of aflibercept compared to controls was seen in the podocytes. Moreover, a 
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significant decrease in VEGF levels was detected comparing days 1 and 7 after 
aflibercept-treatment. Comparing both drugs, VEGF-levels were lower in 
aflibercept samples whereas no effect on VEGF-levels was seen in 
ranibizumab-treated samples. It needs to be further investigated if these 
differences are based on aflibercept´s higher affinity to VEGF or the higher 
stoichiometric concentration administered compared to ranibizumab [42]. 
The relevance of the statistically significant increase in the number of 
fenestrations one day after intravitreal injection of aflibercept compared to all 
other groups, which was not seen after ranibizumab-treatment, also needs to be 
further investigated. It remains unclear if this and the trend of a decrease in the 
number of fenestrations comparing samples one and seven days after injection 
of both drugs is a sign of a reaction of the glomerular endothelium on damage 
or stress or an effect of the anti-angiogenetic drugs. Moreover, studies on 
repeated intravitreal injections as clinically performed are necessary and 
possible effects on patients with renal history have to be monitored [42]. 
3. Conclusion of the work 
In ocular as well as in kidney tissues, the two intravitreally injected drugs could 
be detected already one day after a single injection and also effects on the 
VEGF levels and the number of fenestrations of endothelia were seen this 
early. This shows that the drugs can escape from the blood-retinal barrier and 
reach distant organs like the kidney.  
The first similarity concerning the observed effects was a reduction of the VEGF 
concentration in ciliary body and choriocapillaris and also in the kidney- 
however, here only after aflibercept injection. The second similarity comparing 
eye and kidney samples was a significant reduction of fenestrated endothelium 
in the ciliary body pigmented epithelium and in the choriocapillaris of the retina, 
which was also seen by trend comparing days 1 and 7 after injection of both 
drugs in the kidney. This can be interpreted to be the expected local impact of 
the anti-VEGF drugs in the eye and rises the question if already one day after 
intravitreal injection, an effect of the drug can also be present in the kidney. 
Differences in the distribution patterns of the drugs were not very distinct in the 
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ciliary body and the kidney, but were more evident in the retina. Here, different 
physiological processes in the penetration of the retina were revealed which 
can probably be related to the different molecular structures of the drugs. 
Similar to the results obtained from kidney analyses of these monkeys, a higher 
effect in the reduction of the number of fenestrations was seen for aflibercept-
treated samples in the ciliary body and the choriocapillaris. As a specialty- in 
contrast to eye tissue analyses- the quantification of the number of 
fenestrations in glomerular capillaries revealed a statistically significant increase 
one day after injection of aflibercept which remains unclear. 
Concerning histology, no clinically observable changes in the kidneys of treated 
animals were seen. In eye analyses, vacuoles in the posterior pigmented 
epithelium of the iris of aflibercept-treated animals were observed. Their 
significance and content remains suggestive and needs to be further 
investigated. In retina and choroid, changes in the sense of reduction of the 
lumen of the choriocapillaris, haemolysis, microangiopathy, formation of protein 
complexes, RPE hypertrophy and cell death were seen. Most of these only 
occurred after aflibercept treatment or were here at least more distinct.  
In future studies, all the named aspects should be further studied and also 
reevaluated after repeated intravitreal injections as patients in clinical routine 
usually demand several injections. The fact that the observed changes- 
especially concerning the number of fenestrations and the reduction of VEGF 
levels in the kidney- can not undoubtedly be related to an effect of the drugs but 
might also reflect a reaction of the endothelium on damage or stress should 
advise caution. In particular, the fact that all the described phenomena were 
more distinct or different after treatment with aflibercept should be kept in mind 
as this drug is comparably new. Also, often patients with a history of renal 
disease or diabetes require intravitreal anti-VEGF treatments and might carry a 
higher risk of systemic effects and should thus be monitored. This is of special 
interest as the number of anti-VEGF treatments in wet-AMD rises and as the 
fields of application in ophthalmology are being expanded to other indications 
such as diabetic retinopathy or neovascular glaucoma. 
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V)  Summary 
1. English summary 
Fenestrated capillaries are found in tissues where filtration through a selective barrier 
is needed. This is for example the case in the eye where avascular tissues have to 
be nourished. Fenestrated capillaries of the choriocapillaries of the retina represent 
the blood-retina barrier and in the ciliary body aqueous humor has to be separated 
from the blood. In the kidney, the glomerular capillary wall realizes filtration through 
the blood-urinary barrier. This is realized by specialized fenestrated endothelium and 
this phenotype is strongly dependent on VEGF (vascular endothelial growth factor). 
One of the main functions of the VEGF family of signal molecules is its high 
neoangiogenetic potential. As imbalances can cause severe complication, the 
application of systemic but also local anti-VEGF agents has to be well considered 
and monitored. Systemic application has been found to be effective in several types 
of neoplasms. Occurring side-effects are often unavoidable and dose-dependent. A 
local and very effective anti-VEGF therapy is the intravitreal application of anti-
angiogenetic agents mainly used to treat the wet form of age-related macular 
degeneration (wet AMD). In this approach, the abnormal growth of new blood vessels 
in the retina is inhibited, thus arresting or even reversing patients´ vision loss. 
Presently, three different anti-VEGF agents (bevacizumab, ranibizumab and 
aflibercept) are successfully applied worldwide, but they might differ in their risks to 
cause side-effects due to their molecular design. As comparing the effects of the two 
molecularly different drugs on the kidney was one of the major aims of this study, 
only monkeys have been found to be suitable as study objects because the 
interactions between the Fc domain of antibodies and the Fc receptors are 
comparable to those in humans. The fully human, recombinant fusion protein 
aflibercept (which contains the Fc region of human IgG1) and ranibizumab (a Fc-
domain- free antibody fragment) were compared especially regarding kidney tissues 
in comparison to ocular tissues like the retina/ choroid complex and ciliary body and 
iris. Also, previous studies had revealed that the interactions of these two anti-VEGF 
drugs with the retina and choroid clearly differ. 
Ten cynomolgus monkeys were intravitreally injected either with ranibizumab or 
aflibercept and ophthalmological examinations were performed. Animals were 
sacrificed on days one or seven, respectively and eyes and kidneys were removed. 
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One untreated and one monkey treated with aflibercept´s vehicle served as controls. 
Light and transmission electron microscopic as well as immunohistochemical and 
fluorescent microscopical studies were performed. Moreover, measurements of 
VEGF-plasma levels were performed but all doses were below the detectable limit of 
the assay. Using a systematic uniform random sampling protocol in TEM, the 
numbers of fenestrations per µm in glomerular capillaries were estimated and 
statistically analyzed. 
Both the anti-VEGF drugs ranibizumab and aflibercept could be detected in kidney 
glomeruli by immunohistochemistry. No histological pathologies were found in any of 
the kidneys. Aflibercept significantly reduced VEGF levels in the kidney one and 
seven days after intravitreal injection- an effect that was not observed in ranibizumab 
samples. Also, an effect on the number of fenestrations of glomerular endothelial 
cells was found. Surprisingly, the number of fenestrations of the glomerular 
endothelium was significantly increased the first day after aflibercept-treatment 
compared to control and all other samples. Concerning the two time points (one and 
seven days after injection), a trend of a decrease in the number of fenestrations was 
seen after treatment with both drugs which was only significant for aflibercept. The 
significance and cause of the higher number of fenestrations one day after aflibercept 
injection remains unclear. Stress-related mechanisms as a reaction of the 
endothelium to possible damage or specific interactions between the drug and kidney 
tissues as well as the formation of immune complexes should be further examined. 
Comparing the obtained results to the quantification of fenestrations of the ciliary 
body´s vessels, a reduction of fenestrations was found in all samples with aflibercept 
reducing significantly more fenestrations than ranibizumab. Interestingly, in all eyes 
treated with aflibercept, vacuoles were found in the pigmented epithelium of the iris 
for which no rationale was found. It can only be speculated that these vacuoles are 
congruent with described microcysts of the pigmented iris epithelium or 
accumulations of glycogen in diabetic patients. Equally, further investigations are 
needed to estimate if an apparently higher effectiveness in eliminating fenestrations 
as seen with aflibercept is desirable for example in the treatment of neovascular 
glaucoma. 
In conclusion, the possibility of side-effects occurring after a single intravitreal 
injection of anti-VEGF drugs not only locally in the eye but also in the kidney and 
other distant organs has to be considered as the drugs were detected in the kidneys 
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and as aflibercept reduced VEGF levels in glomeruli. The mechanisms and impacts 
of the detected increase of glomerular endothelial cell fenestrations by aflibercept 
one day after injection need to be further evaluated. Similarly, a possible effect in the 
sense of a reduction of VEGF-dependent fenestrations of glomerular capillaries in the 
course of time and after repeated injections requires further studies. Possible effects 
on the kidney might be more critical for patients with a prior history of nephrological 
disease and with repeated intravitreal injections as clinically practiced for the 
treatment of wet AMD. The observed effects in the kidney as well as in ocular tissues 
and potential differences between ranibizumab and the relatively new aflibercept as 
well as their possible impacts need to be further examined. 
2. Deutsche Zusammenfassung 
Fenestrierte Kapillaren finden sich in Geweben, in denen Filtration durch eine 
selektive Barriere realisiert werden muss. Dies ist beispielsweise im Auge der Fall, 
wo avaskuläre Gewebe ernährt werden müssen. Die fenestrierten Kapillaren der 
Choriocapillaris der Retina stellen die Blut-Retina-Schranke dar und im Ziliarkörper 
müssen Kammerwasser und Blut getrennt werden. In der Niere wird die Filtration von 
Primärharn durch die Blut-Harn-Schranke mit Hilfe der glomerulären Kapillarwand 
realisiert. Verschiedene Untersuchungen haben gezeigt, dass hierfür spezialisiertes 
fenestriertes Endothel notwendig ist und dass dieser Phänotyp stark von VEGF 
(englisch für vaskulärer endothelialer Wachstumsfaktor) abhängig ist. Eine der 
Hauptfunktionen der Familie der VEGF Signalmoleküle ist ihr hohes Potential, das 
Wachstum neuer Blutgefäße- die sogenannte (Neo-) Angiogenese- zu fördern. Da 
jegliche Dysregulation schwere Komplikationen nach sich ziehen kann, sollte die 
Anwendung systemischer aber auch lokaler Angiogenesehemmer wohl durchdacht 
und überwacht werden. In einer Vielzahl von Neoplasmen hat sich die systemische 
Anti-Angiogenesetherapie als effektiv gezeigt. Das Auftreten von Nebenwirkungen in 
Organen wie zum Beispiel Darm und Niere ist oft unvermeidbar und abhängig von 
der applizierten Dosis. Eine lokale und sehr effektive Therapie vor allem der feuchten 
altersbedingten Makuladegeneration stellt die intravitreale Applikation solcher 
Medikamente dar, bei der das überschießende Wachstum neuer Blutgefäße in der 
Retina gehemmt wird. Momentan werden weltweit drei verschiedene Medikamente in 
der Therapie dieser Erkrankung eingesetzt, zwischen denen Unterschiede bezüglich 
des Risikos der Auslösung von unerwünschten Wirkungen bestehen, die vermutlich 
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in deren unterschiedlichem molekularen Design und der Interaktion mit den 
betroffenen Geweben sowie dem Immunsystem des Patienten begründet sind. 
Hierbei scheint vor allem das Vorhandensein einer Fc Domäne von Bedeutung zu 
sein. Deshalb wurden in dieser Studie Affen als Studienobjekte gewählt, da nur so 
die spezifisch Interaktionen der Medikamente mit menschlichen Fc-Rezeptoren 
imitiert werden können. 
Das erste Ziel der Untersuchungen war es, herauszufinden ob eine einzige 
intravitreale Injektion der beiden zu vergleichenden Medikamente möglicherweise 
systemische Nebenwirkungen hervorrufen kann. Des Weiteren interessierte der 
Vergleich der Wirkungen des vollständig humanen rekombinanten Fusionsprotein 
Aflibercept (das die Fc Domäne von humanem IgG1 enthält) und Ranibizumab (ein 
Antikörper-Fragment ohne Fc Domäne) vor allem in Bezug auf ihre Wirkung auf 
Nierenglomeruli und der Vergleich zu okularen Geweben wie dem Retina-Choroid-
Komplex sowie Ziliarkörper und Iris nach einer einzigen intravitrealen Applikation. 
Hierzu wurden zehn Affen der Gattung Macaca entweder Ranibizumab oder 
Aflibercept injiziert. Ophthalmologische Untersuchungen wurden durchgeführt und 
die Tiere ein bzw. sieben Tage nach der Behandlung geopfert, wonach Augen und 
Nieren entnommen wurden. Ein unbehandelter Affe und ein Tier, dem die 
Trägersubstanz von Aflibercepts Injektionslösung injiziert wurden, dienten als 
Kontrollen. Licht- und transelektronenmikroskopische sowie 
fluoreszenzmikroskopische und immunhistologische Untersuchungen der Nieren 
ebenso wie eine Bestimmung der VEGF Level im Plasma wurden durchgeführt.  
 In der Tat konnten beide Medikamente durch immunhistochemische Methoden in 
den untersuchten Nierenglomeruli nachgewiesen werden. Im Gegensatz zu 
Ranibizumab reduzierte Aflibercept die VEGF Level in den Nieren einen sowie 
sieben Tage nach intravitrealer Injektion signifikant. Außerdem zeigte sich ein Effekt 
auf die Anzahl der Fenestrierungen des glomerulären Endothels. 
Überraschenderweise nahm die Anzahl der Fenestrierungen des glomerulären 
Endothels am ersten Tag nach der Injektion von Aflibercept im Vergleich zu 
Kontrollen und Proben aller anderen Affen stark signifikant zu. Die Unterschiede 
zwischen den anderen Proben waren weniger deutlich. Bezüglich der beiden 
Zeitpunkte (ein und sieben Tage nach Injektion) zeigte sich vor allem für die mit 
Aflibercept behandelten Affen eine Abnahme der Fenestrierungen, die als Tendenz 
auch in der Ranibizumab-Gruppe zu sehen war. Histologisch zeigten keine der 
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Nieren pathologische Auffälligkeiten. 
Gemäß früheren Untersuchungen der Retina, wäre eine Verringerung der Anzahl der 
Fenestrierungen durch antiangiogenetische Behandling auch in der Niere mit ihrem 
vergleichbaren Phänotyp erwartet worden. Bedeutung und Ursache der Zunahme an 
Fenestrierungen einen Tag nach der Injektion von Aflibercept bleibt unklar. 
Stressbedingte Mechanismen wie zum Beispiel eine Reaktion des Endothels auf 
mögliche Schädigungen oder spezifische Interaktionen des Medikaments mit 
Nierengewebe sowie die Bildung von Immunkomplexen sollten untersucht werden. 
Die fenestrierten Kapillaren des Ziliarkörpers tragen auch zur Aufrechterhaltung des 
intraokularen Drucks bei. Auch bei der Quatifizierung dieser Fenestrierungen wurde 
eine Reduzierung der Anzahl in allen Proben gefunden, wobei der Effekt von 
Aflibercept sowohl einen als auch sieben Tage nach Injektion im Vergleich zu 
Ranibizumab signifikant höher war. Interessanterweise wurden in der Iris aller mit 
Aflibercept behandelter Tiere Vakuolen gefunden. Es wurde bisher noch keine 
abschließende Erklärung für deren Auftreten gefunden und die scheinbar höhere 
Effektivität von Aflibercept muss hier noch weiter untersucht und bewertet werden.  
Zusammenfassend sollte beachtet werden, dass Nebenwirkungen nach intravitrealer 
Injektion von antiangiogenetischen Medikamenten nicht nur lokal im Auge, sondern 
auch in der Niere und anderen entfernten Organen auftreten können. Hinweise 
hierfür liefert diese Studie, da die Medikamente in allen untersuchten Nieren 
nachgewiesen wurden und da Aflibercept das VEGF Level in den untersuchten 
Glomeruli schon nach einer einzigen Injektion reduzierte. Mechanismen und 
Auswirkungen der erhöhten Anzahl an Fenestrierungen im Endothel der 
glomerulären Kapillaren einen Tag nach Aflibercept-Injektion sollten weiter 
untersucht werden. Ebenso muss ein möglicher Effekt im Sinne einer Reduktion der 
VEGF-abhängigen Fenestrierung der Nierenkapillaren im Laufe der Zeit und nach 
wiederholten Injektionen näher untersucht werden. Mögliche die Niere betreffende 
Effekte wären wahrscheinlich für Patienten mit nephrologischen Vorerkrankungen 
sowie bei wiederholter intravitrealer Injektion, wie es klinisch in der Behandlung der 
feuchten altersbedingten Makuladegeneration die Regel ist, kritischer.
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